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GLOSSARY OF ABBREVIATIONS 
                                   oC                     Degree centigrade 
                                   FT-IR                     Fourier Transform Infra Red 
                                   µg                     Microgram 
                                   nm                                                Nano metres 
                                   mg                     Milligram 
                                    ml                                                                 Millilitres 
                                    min                                                                  Minutes 
                                   hr                                                   Hours 
                                   %                      Percent/percentage 
                                   q.s                                                 Quantity sufficient                       
                                   rpm                     Revolutions per Minute 
                                   RH                                         Relative Humidity 
                                   HRT                                              Hormone replacement therapy 
                                   BCS                                              Biopharmaceutical classification  
                                                                                                                           System 
                                   SMEDDS                                     Self microemulsifying drug delivery  
                                                                                                                      System 
                                   SCF                                               Super critical fluid  
                                   GIT                                                Gastro Intestinal Tract 
                                           Tc                                                                           Critical Temperature 
                                    Tp                                                                          Critical Pressure 
                                    CD                                                Cyclodextrins  
                                    CMC                                             Critical micelle concentration 
                                    SDS                                              Sodium dodecyl sulphate 
                                    FNA                                              Fine needle aspiration 
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                                     CT                                                 Computerised tomography 
                                     MRI                                               Magnetic resonance imaging 
                                     DRE                                               Digital rectal examination 
                                     PEG                                                Polyethylene glycol 
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ABSTRACT 
 
                 Megesterol acetate a synthetic derivative of naturally occurring steroidal hormone 
progesterone, used in the treatment of breast cancer. The drug is poorly soluble and 
thermosensitive. The rate of dissolution and its bioavailability is less. In this investigation an 
attempt was made to develop novel drug to enhance the dissolution of solid oral formulation 
of Megesterol acetate using solid dispersion and hydrotropic techniques. The tablets can be 
prepared using less complicated and less expensive excipients, process, as well as to fulfill 
better therapeutic action for pharmaceutical use. In the study the approach of hydrotropic 
technique used hydrotropic agents like sodium acetate, sodium benzoate, sodium citrate and 
urea. In the solid dispersion technique PEG 6000 is used as a carrier. The dissolution pattern 
of optimized formulation was compared with Innovator product and it was found to be 
superior to the Innovator product. 
Key words: Megesterol acetate, solid dispersion technique, hydrotropic techniques. 
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SCOPE AND OBJECT 
                         The last 50 yrs has seen a better understanding of the causes and treatment of 
breast cancer. Hence, early detection and technology has improved the prognosis of cancer 
patient to an unprecedented level. Megesterol acetate is a novel synthetic antineoplastic and 
progestational drug in the treatment of breast cancer. It is a new chemical entity, belongs to 
BCS class II, which exhibits low aqueous solubility and high membrane permeability that 
leads to poor bioavailability. To develop the formulation the following challenges need to 
overcome. 
1. Poor solubility 
2. Thermal degradation 
3. Potent drug  
4. Poor stability 
5. Long elimination half life 
6. Onset of action is slow 
                          Conventional megesterol acetate tablets are practically insoluble in water and 
have slow onset of action and poor bioavailability therefore cannot give effective therapy. 
Hence I have designed. Formulation development of megesterol acetate immediate release 
tablets provide following benefits; 
1. Megesterol acetate has been to be effective therapy for the treatment of breast and 
prostate cancer. 
2. Improvement of bioavailability, avoidance of tissue accumulation. 
3. Gives assurance for long term stability. 
4. Improve patient compliance 
5. Improve oral absorption 
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The present study is to develop immediate release megesterol acetate tablets by using a novel 
technique mixed hydrotropy with different polymers by using different hydrotropic agents 
and super disintigrents at different ratios.  
To fulfil the above scope the major objects of the investigations are as follows 
1. To design megesterol acetate immediate release tablets. 
2. To conduct preformulation studies of the API. 
3. To prepare poorly soluble megesterol acetate tablets by using solid dispersion and 
mixed hydrotropy technique. 
4. The primary object of this study was to enhance solubility of megesterol acetate. 
5. To study the influence of polymer concentration on the megesterol acetate to optimise 
best polymer.  
6. To optimise better technique. 
7. To determine rate of dissolution. 
8. To evaluate kinetic mechanisms of drug release. 
9. To evaluate and prepare tablets as per pharmacopeia standards. 
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CHAPTER-1 
INTRODUCTION 
 
1.1.CANCER 
A tumour is a swelling or mass resulting from abnormal growth of tissue. Cancer is likely to 
damage important or vital organs or tissue in any or all part of the body. 
Cancer is a class of diseases characterized by out-of-control cell growth. There are over 100 
different types of cancer, and each is classified by the type of cell that is initially affected 
1.1.2. Types of cancer 
1. Leukaemia: cancer of blood in which white blood cells shown an abnormal increase 
2. Carcinomas: cancer of epithelial cells 
3. Sarcomas: cancer of connective tissue  
4. Lymphomas: cancer of lymphatic tissue 
5. Lipomas: cancer of adipose tissue  
1.1.3. Location for cancer 
Cancer occurring in any part of body has unique characteristic  
1. Bile ducts:  
The bile ducts may become involved either with cancer developing within the ducts 
themselves or with cancer in adjacent structures. The earlier significant symptom in jaundice, 
which results from continuous obstruction to flow of bile. 
2. Breast: 
The breast is the common site of cancer in women lumps in the breast is caused by cancer. So 
the physician is dealing with early case of lump in the breast, has to differentiate between 
benign tumour and malignant one. 
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3. Bone:  
The cancer of bone grows due to blood streams or from some adjacent organ or tissues. Bones 
cancer causes pain swelling and weakens the bone. 
4. Esophagus:  
Cancer of esophagus is also common it may occur in any part of organ from the throat on 
down, but mostly in the lower part. Due to cancer of esophagus there is difficulty in the 
swallowing. 
5. Lung:  
The cancer of lings is becoming more prominent in our country which causes maximum death 
in our country. The main reason for the lung cancer is cigarette without treatment the survival 
rate for the usual type of lung cancer is zero. In the total type of cancer 40% are infected by 
the lung cancer. 
6. Ovary:  
This is the most dreadful cancer amongst the women. The most of the women die due to 
cancer of ovary in our country. This can be treated by surgery 
7. Pancreas: 
 The cancer of pancreas causes the pain in the upper part of the membrane. Cancer of 
pancreas also causes jaundice. The cancer is highly malignant cancer of pancreas is more 
common in men than women. This can be removed by surgery. 
8. Stomach:  
Cancer of stomach is also more common in men than women. Symptoms are indigestion, loss 
of appetite, loss of weight etc. Surgical removal without delay of all or part of the stomach is 
only proper treatment. 
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9. Thyroid:  
This cancer causes the enlargement of thyroid gland, development of nodules in the gland. 
The removal of these nodules is very necessary for the treatment of this disease. 
10. Tounge:  
Cancer of tounge cause more death than any other cancer within the mouth. It results 
persistent inflammation. 
1.2. BREAST CANCER 
Breast tumours are usually caused by an overgrowth of the cells lining the breast ducts. 
They can be either benign or malignant. In a benign tumour, the cells grow abnormally and 
form a lump. But they don’t spread to other parts of the body and so is not cancer. The most 
common type of benign breast tumour is called a fibro adenoma. This may need to be 
surgically removed to confirm the diagnosis. No other treatment is necessary. In a malignant 
tumour, the cancer cells have the ability to spread beyond the breast if they are left untreated. 
For example, if a malignant tumour in the breast isn’t treated, it may grow into the muscles 
that lie under the breast. It can also grow into the skin covering the breast. Sometimes cells 
break away from the original (primary) cancer and spread to other organs in the body. They 
can spread through the bloodstream or lymphatic system. When these cells reach a new area 
they may go on dividing and form a new tumour. The new tumour is often called a secondary 
or metastasis. Breast cancer occurs when cells within the breast ducts and lobules become 
cancerous. If caught at an early stage, breast cancer can often be cured. If the cancer has 
spread to other areas of the body it can’t usually be cured, but it can normally be effectively 
controlled for a long time. 
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1.2.1. Risk factors:  
 Age:  
The risk of developing breast cancer increases with age. It’s rare in women under 35. 8 
out of 10 breast cancers (80%) occur in women aged 50 or over. 
 Previous cancer:  
1. Breast cancer, including ductal carcinoma in situ 
2. Lobular carcinoma in situ 
3. An over-production of slightly abnormal cells called atypical ductal hyperplasia 
4. Radiotherapy to the chest to treat Hodgkin lymphoma at a young age 
 Hormonal factors: 
1. Taking combined hormone replacement therapy (HRT) containing oestrogen and 
progesterone over several years (if you’re over 50) 
2. Starting your periods early (under 12) or having a late menopause (after 50) 
3. Taking the contraceptive pill (but the risk reduces if you stop taking it). 
 Certain lifestyle:  
These include drinking more than two units of alcohol a day over many years, being 
overweight and smoking heavily.  
 Genetic factors: 
 Family history only 5–10% (1 in 20–1 in 10) of breast cancers is thought to be linked to 
an inherited breast cancer gene. 
 1.2.2. Symptoms 
Symptoms of breast cancer can include: 
• A lump in the breast 
• A change in the size or shape of the breast 
• Dimpling of the skin or thickening in the breast tissue 
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• A nipple that’s turned in (inverted) 
• A rash (like eczema) on the nipple 
• Discharge from the nipple 
• Swelling or a lump in the armpit. 
1.2.3. Breast cancer diagnosed 
 Mammogram 
 Fine needle aspiration (FNA) 
 Ultrasound and FNA of the lymph Nodes 
 Biopsy of tissue  
 Needle (core) biopsy 
 CT (computerised tomography) scan 
 MRI (magnetic resonance imaging) scan 
 A breast ultrasound 
 X- Rays ultrasound 
1.3. PROSTATE CANCER  
  Prostate cancer is a form of cancer that develops in the prostate, a gland in the male 
reproductive system. Most prostate cancers are slow growing;[1] however, there are cases of 
aggressive prostate cancers.[2] The cancer cells may metastasize (spread) from the prostate to 
other parts of the body, particularly the bones and lymph nodes. Prostate cancer may cause 
pain, difficulty in urinating, problems during sexual intercourse, or erectile dysfunction. Other 
symptoms can potentially develop during later stages of the disease. 
1.3.1. Symptoms 
 These include frequent urination, nocturia (increased urination at night),  
 Difficulty starting and maintaining a steady stream of urine,  
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 Hematuria (blood in the urine), and 
  Dysuria (painful urination). 
 Prostate cancer is associated with urinary dysfunction as the prostate gland surrounds the 
prostatic urethra. Changes within the gland, therefore, directly affect urinary function. 
Advanced prostate cancer can spread to other parts of the body, possibly causing additional 
symptoms. The most common symptom is bone pain, often in the vertebrae (bones of the 
spine), pelvis, or ribs. Spread of cancer into other bones such as the femur is usually to the 
proximal part of the bone. Prostate cancer in the spine can also compress the spinal cord, 
causing leg weakness and urinary and fecal incontinence. 
1.3.2. Risk factors 
A complete understanding of the causes of prostate cancer remains elusive.[13] The primary 
risk factors are obesity, age and family history. Prostate cancer is very uncommon in men 
younger than 45, but becomes more common with advancing age 
a. Genetic 
Genetic background may contribute to prostate cancer risk, as suggested by associations with 
race, family, and specific gene variants. 
b. Viral 
In 2006, a previously unknown retrovirus, Xenotropic MuLV-related virus or XMRV, was 
associated with human prostate tumors, but subsequent reports on the virus were 
contradictory and the original 2006 finding was instead due to a previously undetected 
contamination.  
c. Sexual factors 
Several case-control studies have shown that having many lifetime sexual partners or starting 
sexual activity early in life substantially increases the risk of prostate cancer 
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1.3.3. Diagnosis 
 Biopsy,  
 Digital rectal examination (DRE). 
  Cystoscopy  
 Transrectal ultrasonography  
 
                 
Fig no. 1. Diseased and normal prostate gland 
1.4. Different types of chemotherapy drugs 
Chemotherapy drugs can be divided into several groups based on factors such as how they 
work, their chemical structure, and their relationship to another drug. Because some drugs act 
in more than one way, they may belong to more than one group.  
1.4.1. Alkylating agents 
 Nitrogen mustards: such as mechlorethamine (nitrogen mustard), chlorambucil,  
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 Nitrosoureas: which include streptozocin, carmustine (BCNU), and lomustine  
 Alkyl sulfonates: busulfan  
 Triazines: dacarbazine (DTIC) and temozolomide (Temodar®) 
 Ethylenimines: thiotepa and altretamine (hexamethylmelamine) 
1.4.2. Antimetabolites 
 5-fluorouracil (5-FU), 6-mercaptopurine (6-MP) ,Capecitabine (Xeloda®), Cladribine, 
Floxuridine, Hydroxyurea, Methotrexate, Pentostatin, Thioguanine 
1.4.3. Anti-tumour antibiotics 
           Anthracyclines 
 Daunorubicin , Doxorubicin (Adriamycin®) , Epirubicin , Idarubicin  
1.4.4. Other anti-tumor antibiotics 
         Topoisomerase inhibitors 
 Topoisomerase I inhibitors:  Topotecan and irinotecan  
 Topoisomerase II inhibitors:  Etoposide, teniposide, Mitoxantrone. 
1.4.5. Mitotic inhibitors 
 Taxanes: paclitaxel (Taxol®) and docetaxel (Taxotere®) 
 Epothilones: ixabepilone (Ixempra®) 
 Vinca alkaloids: vinblastine (Velban®), vincristine (Oncovin®), and vinorelbine  
 Estramustine (Emcyt®) 
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1.4.6. Corticosteroids 
 Prednisone, methylprednisolone (Solumedrol®), and dexamethasone (Decadron®).  
1.4.7. Other types of cancer drugs 
a. Targeted therapies 
 Imatinib (Gleevec®), gefitinib (Iressa®), sunitinib (Sutent®) and bortezomib (Velcade®).  
b. Differentiating agents 
 Retinoids, tretinoin (ATRA or Atralin®) and bexarotene (Targretin®), as well as arsenic 
trioxide (Arsenox®). 
c. Hormone therapy 
 The anti-estrogens: fulvestrant (Faslodex®), tamoxifen, and toremifene (Fareston®) 
 Aromatase inhibitors: anastrozole (Arimidex®), exemestane (Aromasin®) 
 Progestins:Megesterol acetate (Megace®) 
 Estrogens 
 Anti-androgens: bicalutamide (Casodex®), flutamide (Eulexin®) 
d. Immunotherapy 
 Monoclonal antibody therapy (passive immunotherapies), such as rituximab (Rituxan®) 
and alemtuzumab (Campath®)  
 Non-specific immunotherapies and adjuvants (other substances or cells that boost the 
immune response), such as BCG, interleukin-2 (IL-2), and interferon-alfa  
 Immunomodulating drugs, for instance, thalidomide and lenalidomide (Revlimid®) 
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1.5. SOLUBILITY: 
Solubility is the property of a solid, liquid, or gaseous chemical substance called solute to 
dissolve in a solid, liquid, or gaseous solvent to form a homogeneous solution of the 
maximum quantity of solute in a certain quantity of solvent at a specified temperature and 
pressure  
1.5.1. Process of Solubilisation: 
The process of solubilization contains three steps. First step involves the separation of the 
molecules of the solvent to provide space in the solvent for the solute, second step involves 
the breaking of intermolecular or inter-ionic bonds in the solute, and third & final step 
involves the interaction between the solvent and the solute molecule or ion.  
 
                              TABLE 1: USP and BP solubility criteria 
                                    
                         Descriptive term             Part of solvent required per part of solute 
                          Very soluble 
                           Freely soluble                
                           Soluble  
                           Sparingly soluble           
                           Slightly soluble                                                    
                           Very Slightly soluble         
                           Practically insoluble      
              
            Less than 1  
            From 1 to 10 
            From 10 to 30 
            From 30 to 100 
From 100 to 1000  
         From 1000 to 10,000 
             10,000 and over 
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Step 1: Holes open in the solvent 
 
Step2: Molecules of the solid breaks away from the bulk 
 
 
 
Step 3:The freed solid molecule is integrated into the hole in the solvent 
 
 
 
Fig no. 2 Solubilisation steps 
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1.5.2. BCS CLASSES: 
According to the BCS (Biopharmaceutical classification system) all drugs have been divided 
into four classes: 
 Class I— high soluble and high permeable, 
 Class II—low soluble and high permeable, 
 Class III—high soluble and low permeable and 
 Class IV—low soluble and low permeable. 
1.5.3. Importance of Solubility: 
1. Especially for class II (low solubility and high permeability) substances according to the 
BCS, the bioavailability may be enhanced by increasing the solubility and dissolution rate of 
the drug in the gastro-intestinal fluids. 
2. As for BCS class II drugs rate limiting step is drug release from the dosage form and 
solubility in the gastric fluid and not the absorption, so increasing the solubility in turn 
increases the bioavailability for BCS class II drugs. 
3. The poor solubility and low dissolution rate of poorly water soluble drugs in the aqueous 
gastrointestinal fluids often cause insufficient bioavailability. so increasing the solubility in 
turn increases the bioavailability for them. 
4. Solubility is one of the important parameters to achieve desired concentration of drug in 
systemic circulation for achieving required pharmacological response. 
5. Poorly water soluble drugs often require high doses and have administration frequency in 
order to reach therapeutic plasma concentrations after oral administration. 
6. Low aqueous solubility is the major problem encountered with formulation development of 
new chemical entities as well as generic development. 
7. Any drug to be absorbed must be present in the form of an aqueous solution at the site of 
absorption. 
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8. Water is the solvent of choice for liquid pharmaceutical formulations. 
9. Most of the drugs are either weakly acidic or weakly basic having poor aqueous solubility. 
10. Poorly water soluble drugs having slow drug absorption leads to inadequate and variable 
bioavailability and gastrointestinal mucosal toxicity. 
11. For orally administered drugs solubility is the most important one rate limiting parameter 
to achieve their desired concentration in systemic circulation for pharmacological response. 
 
1.5.4. Enhancement of solubilization and bioavailability of poorly soluble drugs 
 Solubilization of poorly soluble drugs is a frequently encountered challenge in screening 
studies of new chemical entities as well as in formulation design and development .A number 
of methodologies can be adapted to improve solubilization of poor water soluble drug and 
further to improve its bioavailability. Orally administered drugs completely absorb only when 
they show fair solubility in gastric medium and such drugs shows good bioavailability.  The 
techniques generally employed for solubilization of drug includes micronization, chemical 
modification, pH adjustment, solid dispersion, complexation, co?solvency, micellar 
solubilization, hydrotropy etc. 
                                  Actually, only solubilized drug molecules can be absorbed by the 
cellular membranes to subsequently reach the site of drug action . Any drug to be absorbed 
must be present in the form of an aqueous solution at the site of absorption . As Solubility & 
permeability is the deciding factor for the in-vivo absorption of the drug, these can be altered 
or modified by enhancement techniques like Poorly soluble compounds belongs to class II of 
BCS. These poorly water soluble drugs are allied with slow drug absorption leading to 
inadequate and variable bioavailability and gastrointestinal mucosal toxicity. Therefore, the 
improvement of drug solubility thereby its oral bio-availability remains one of most 
challenging aspects of drug development process especially for oral drug delivery system. 
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These in vivo and in vitro characteristics and the difficulties in achieving predictable and 
reproducible in vivo/in vitro correlations are often sufficiently difficult to develop formulation 
on many newly synthesized compounds due to solubility issues. 
1.6. TECHNIQUES OF SOLUBILITY AND BIOAVAILABILITY ENHANCEMENT 
There are various techniques available to improve the solubility of poorly soluble drugs. 
Some of the approaches to improve the solubility are: 
(1) pH adjustment 
It is well documented that the influence of the changes in pH within the gastrointestinal tract 
upon the bioavailability of pharmaceuticals. The absorption of drug is largely dependent upon 
diffusion, which varies with pH of the individual regions within the gastrointestinal tract, the 
pKa of the drug and permeability, which are not only moderated by the surface area of the 
region in which it is released, but also the regional pH effects upon drug ionization. By 
applying a pH change, poorly water soluble drugs with parts of the molecule that can be 
protonated (base) or deprotonated (acid) may potentially be dissolved in water.  
 (2) Micro-emulsion 
A micro emulsion is an optically clear pre-concentrate, isotropic, thermo dynamically stable 
transparent (or translucent) system, containing a mixture of oil, hydrophilic surfactant and 
hydrophilic solvent which dissolves a poorly water soluble drug. Upon contact with water, the 
formulations spontaneously disperse (or ‘self emulsifies’) to form a very clear emulsion of 
exceedingly small and uniform oil droplets containing the solubilized poorly soluble drug. 
Micro-emulsions have been employed to increase the solubility of many drugs that are 
practically insoluble in water, along with incorporation of proteins for oral, parenteral, as well 
as percutaneous/transdermal use .These homogeneous systems, which can be prepared over a 
wide range of surfactant concentration and oil to water ratio, are all fluids of low viscosity. 
Surfactants, surfactant mixtures and co-surfactants in microemulsions play an important role 
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in improving the solubility of drugs formulated as micro-emulsions. An anhydrous system of 
micro-emulsions is that self microemulsifying drug delivery system (SMEDDS) or micro-
emulsion pre-concentrate. It is composed of oil, surfactant and co-surfactant and has the 
ability to form o/w microemulsion when dispersed in aqueous phase under gentle agitation 
 (3) Self-emulsifying drug delivery systems 
Self-emulsifying or self-micro emulsifying systems use the concept of in situ formation of 
emulsion in the gastrointestinal tract. The mixture of oil, surfactant, co-surfactant, one or 
more hydrophilic solvents and co-solvent forms a transparent isotropic solution that is known 
as the self-emulsifying drug delivery system (SEDDS) , in the absence of external phase 
(water) and forms fine o/w emulsions or micro-emulsions spontaneously upon dilution by the 
aqueous phase in the GIT and is used for improving lipophillic drug dissolution and 
absorption.  
(4) Manipulation of solid state 
From the stability and bioavailability aspects, the crystalline form of a drug is pharmaceutical 
importance. Polymorphism (existence of a drug substance in multiple crystalline forms) can 
cause variations in melting point, density, stability and drug solubility as these properties 
depend on the escaping tendency of the molecules from a particular crystalline structure. As a 
rule, for a drug that have the highest order of crystallinity is the most stable form, exists in 
multiple polymorphic forms, i.e. with the least amount of free energy, and, consequently, 
possesses the highest melting point and the least solubility. By controlling the crystallization 
process, amorphous or meta stable forms of drugs possessing high free energy can be forcibly 
created. They offer the advantage of higher solubility but suffer from stability issues unless 
stabilizers intended to inhibit crystal growth are incorporated in the formulation .  
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(5) Particle size reduction 
The bioavailability of poorly soluble drugs is often intrinsically related to drug particle size. 
By reducing particle size, the increased surface area may improve the dissolution properties of 
the drug to allow a wider range of formulation approaches and delivery technologies . The 
larger surface area allows a greater interaction with the solvent which cause increase in 
solubility . Conventional methods of particle size reduction, such as comminution and spray 
drying, rely upon mechanical stress to disaggregate the active compound. Nowadays Particle 
size reduction can be achieved by micronization and nano-suspension.  
 In Micronization of drugs is done by milling techniques using jet mill, rotor stator colloid 
mills etc.  
 Nano-suspension is another technique which is sub-micron colloidal dispersion of pure 
particles of drug, which are stabilized by surfactants.  
Nano-suspensions are produced by homogenization and wet milling process [43]. Re-
crystallization of poorly soluble materials using liquid solvents and anti-solvents has also 
been employed successfully to reduce particle size.  
(6) Super critical fluid (SCF) process 
Another novel nano-sizing and solubilization technology whose application has increased in 
recent years is particle size reduction via supercritical fluid (SCF) processes. The number of 
applications and technologies involving supercritical fluids has also grown explosively. It has 
been known for more than a century that supercritical fluids (SCFs) can dissolve nonvolatile 
solvents, with the critical point of carbon dioxide, the most widely used supercritical fluid. 
Super critical fluids are fluids whose temperature and pressure are greater than its critical 
temperature (Tc) and critical pressure (Tp), allowing it to assume the properties of both a 
liquid and a gas. It is safe, environmentally friendly, and economical. The low operating 
conditions (temperature and pressure) make SCFs attractive for pharmaceutical research. At 
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nearcritical temperatures, SCFs are high compressible, allowing moderate changes in pressure 
to greatly alter the density and mass transport characteristics of a fluid that largely determine 
its solvent power . A SCF exists as a single phase above its critical temperature (Tc) and 
pressure (Pc). SCFs have properties useful to product processing because they are 
intermediate between those of pure liquid and gas (i.e., liquid-like density, gas-like 
compressibility and viscosity and higher diffusivity than liquids).At near-critical 
temperatures, SCFs are high compressible, allowing moderate changes in pressure to greatly 
alter the density and mass transport characteristics of a fluid that largely determine its solvent 
power .  
 (7) Inclusion complexes/complexation 
Lipophillic drug-cyclodextrin complexes, commonly known as inclusion complexes, can be 
formed simply by adding the drug and excipients together, resulting in enhanced drug 
solubilization. Cyclodextrins (CD) are a group of structurally-related cyclic oligosaccharides 
that have a polar cavity and hydrophilic external surface. Inclusion complexes are formed by 
the insertion of the nonpolar molecule or the nonpolar region of one molecule (known as 
guest) into the cavity of another molecule or group of molecules (known as host). The most 
commonly used host molecules are cyclodextrins. Cyclodextrins consisting of 6, 7 and 8 D 
glucopyranosyl units connected to Q -1, 4 glycosidic linkages are known as Q, R, D, 
cyclodextrins, respectively. Derivatives of R-cyclodextrin with increased water solubility (e.g. 
hydroxypropyl-R-cyclodextrin HP-R-CD) are most commonly used in pharmaceutical 
formulation.   
 (8) Co-solvency 
The solubility of a poorly water soluble drug can be increased frequently by the addition of a 
water miscible solvent in which the drug has good solubility known as cosolvents. Co 
solvents are mixtures of water and one or more water miscible solvents used to create a 
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solution with enhanced solubility for poorly soluble compounds. Historically, this is one of 
the most widely used techniques because it is simple to produce and evaluate Co-solvency has 
been utilized in different formulations including solids and liquids. Examples of solvents used 
in co-solvent mixtures are PEG 300, propylene glycol or ethanol. Various concentrations (5-
40%) of the solid binary systems with polyethylene glycol 6000 were employed to increase 
solubility and dissolution.  Co- Solvents can increase the solubility of poorly soluble 
compounds several thousand times compared to the aqueous solubility of the drug alone.  
(9) Miceller solubilization 
The use of surfactants to improve the dissolution performance of poorly soluble drug products 
has also been successfully employed. Surfactants can lower surface tension and improve the 
dissolution of lipophillic drugs in aqueous medium. They can also be used to stabilize drug 
suspensions. When the concentration of surfactants exceeds their critical micelle 
concentration (CMC, which is in the range of 0.05-0.10% for most surfactants), micelle 
formation occurs, entrapping the drugs within the micelles .This process is known as 
micellisation and generally results in enhanced solubility of poorly soluble drugs. Commonly 
used non-ionic surfactants include polysorbates, polyoxyethylated castor oil, 
polyoxyethylated glycerides, lauroyl macroglycerides and mono- and di-fatty acid esters of 
low molecular weight polyethylene glycols. Surfactants are also often used to stabilize micro-
emulsions and suspensions into which drugs are dissolved. 
(10) Hydrotrophy 
Hydrotrophy is a solubilization process whereby addition of a large amount of second solute 
results in an increase in the aqueous solubility of another solute. Hydrotrophy designate the 
increase in solubility in water due to the presence of large amount of additives. The 
mechanism by which it improves solubility is more closely related to complexation involving 
a weak interaction between the hydrotropic agents like sodium benzoate, sodium acetate, 
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sodium alginate, urea and the poorly soluble drugs. Solute consists of alkali metal salts of 
various organic acids. Hydrotropic agents are ionic organic salts. Additives or salts that 
increase solubility in given solvent are said to “salt in” the solute and those salts that decrease 
solubility “salt out” the solute. Several salts with large anions or cations that are themselves 
very soluble in water result in “salting in” of non electrolytes called “hydrotropic salts” a 
phenomenon known as “hydrotropism”. Hydrotropic solutions do not show colloidal 
properties and involve a weak interaction between the hydrotropic agent and solute.  
                                              The classification of hydrotropes on the basis of molecular 
structure is difficult, since a wide variety of compounds have been reported to exhibit 
hydrotropic behavior. Specific examples may include ethanol, aromatic alcohols like 
resorcinol, pyrogallol, catechol, aand bnaphthols and salicylates, alkaloids like caffeine and 
nicotine, ionic surfactants like diacids, SDS (sodium dodecyl sulphate) and dodecylated 
oxidibenzene.  
(11) Solid Dispersions 
In this technique, a poorly soluble drug is dispersed in a highly soluble solid hydrophilic 
matrix, which enhances the dissolution of the drug. Solid dispersion techniques can yield 
eutectic (non-molecular level mixing) or solid solution (molecular level mixing) products.  
Eutectic dispersions are homogeneous dispersions of crystalline or amorphous drugs in 
crystalline or amorphous carriers. In the solid solution form, the drug could be partially or 
completely soluble in the dispersing matrix.  
                                        A solid dispersion of griseofulvin and polyethylene glycol 8000 
(Gris- PEG®) is commercially available. Presence of the drug in microcrystalline state, 
improved wettability and formation of high free energy amorphous forms of the drug during 
solid dispersion formation contribute towards enhancement of drug solubilization.  
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Solid dispersions represent a useful pharmaceutical technique for increasing the dissolution, 
absorption and therapeutic efficacy of drugs in dosage forms. The most commonly used 
hydrophilic carriers for solid dispersions include polyvinylpyrrolidone, polyethylene glycols, 
Plasdone-S630, Tween-80, Docusate sodium, Myrj-52, Pluronic-F68 and Sodium Lauryl 
Sulphate used 
Various techniques to prepare the solid dispersion of hydrophobic drugs to improve their 
aqueous solubility 
1. Hot melt method (fusion method)  
The physical mixture of a drug and a watersoluble carrier was heated directly until it melted. 
The melted mixture was then cooled and solidified rapidly in an ice bath under rigorous 
stirring. The final solid mass was crushed, pulverized, and sieved, which can be compressed 
into tablets with the help of tabletting agents. The melting point of a binary system is 
dependent upon its composition, i.e., the selection of the carrier and the weight fraction of the 
drug in the system. 
2. Solvent Evaporation Method 
The first to dissolve both the drug and the carrier in a common solvent and then evaporate the 
solvent under vacuum to produce a solid solution. This enabled them to produce a solid 
solution of the highly lipophillic R-carotene in the highly water soluble carrier 
polyvinylpyrrolidone. Many investigators studied solid dispersion of meloxicam15, naproxen 
and nimesulide using solvent evaporation technique. 
3. Hot melt extrusion 
Hot melt extrusion is essentially the same as the fusion method except that intense mixing of 
the components is induced by the extruder. Just like in the traditional fusion process, 
miscibility of drug and matrix can be a problem. High shear forces resulting in high local 
temperature in the extruder is a problem for heat sensitive materials. 
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(12) Nano-suspension 
Nano-suspension technology has been developed as a promising candidate for efficient 
delivery of hydrophobic drugs. This technology is applied to poorly soluble drugs that are 
insoluble in both water and oils. The particle size distribution of the solid particles in nano-
suspensions is usually less than one micron with an average particle size ranging between 200 
and 600 nm. There are various methods for preparation of Nano-suspension includes Media 
Milling (Nanocrystals), High Pressure Homogenization in water (Dissocubes), High Pressure 
Homogenization in nonaqueous media (Nanopure) and combination of Precipitation and 
High-Pressure Homogenization (Nanoedege).  
(13) Cryogenic techniques 
Cryogenic techniques have been developed to creating nano-structured amorphous drug 
particles with high degree of porosity at very low temperature conditions so enhance the 
dissolution rate of drugs. Cryogenic inventions can be defined by the type of injection device 
(capillary, rotary, pneumatic and ultrasonic nozzle), location of nozzle (above or under the 
liquid level) and the composition of cryogenic liquid (hydro fluoro alkanes, N2, Ar, O2 and 
organic solvents). After cryogenic processing, dry powder can be obtained by various drying 
processes (spray freeze drying, atmospheric freeze drying, vacuum freeze drying and 
lyophilization).  
(14) Nano-crystallization 
The nanocrystallization is defined as a way of diminishing drug particles to the size range of 
1-1000 nanometers. There are two distinct methods used for producing nanocrystals; ’bottom-
up’ and ’top-down’ development. The top-down methods (i.e. Milling and High pressure 
homogenization) start milling down from macroscopic level, e.g. from a powder that is 
micron sized. In bottom-up methods (i.e. Precipitation and Cryo-vacuum method), nanoscale 
materials are chemically composed from atomic and molecular components. 
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1.7. IMMEDIATE RELEASE DRUG DELIVERY SYSTEM 
Immediate release drug delivery system is also conventional type of drug delivery 
system and it is defined as - Immediate release tablets are designed to disintegrate and release 
their medicaments with no special rate controlling features such as special coatings and other 
techniques. 
1.7.1. Advantages of immediate release drug delivery systems2 
 Release the drug immediately. 
 More flexibility for adjusting the dose. 
 It can be prepared with minimum dose of drug. 
 There is no dose dumping problem. 
 Immediate release drug delivery systems used in both initial stage and final 
stage of disease. 
Immediate release tablets (conventional tablets): The tablet is intended to be released 
rapidly after administration or the tablet is dissolved and administered as solution. It is the 
most common type and includes: 
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CHAPTER-2 
DRUG PROFILE 
 
2.1. 1. MEGESTEROL ACETATE: 
Generic name                             :          Megace and Megace ES 
Category                                     :          Antineoplastic Agents 
Chemical structure                    :    
 
Chemical and IUPAC name     :         (1S, 2R,10R,11S,14R,15S)-14-acetyl-14-hydroxy-2,15-  
                                                             dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca6,8- 
                                                             dien-5-one. 
Molecular formula                    :              C24H32O4 
Molecular weight                      :              384.509 g/mol 
Physical data: 
Colour                  :        white, crystalline solid 
Odour                   :        none. 
Taste                   :        bitter 
Solubility                  :               practically insoluble in water, soluble in acetone, 
                                                                   sparingly soluble in alcohol. 
                                     
Storage Conditions                :        Protected from light. 
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Melting point                 :        about 217 °C. 
                                                                                              
 Mechanism of action of Megesterol acetate: 
The precise mechanism by which Megesterol acetate produces effects in anorexia and cachexia is 
unknown at the present time, but its progestin antitumour activity may involve suppression of 
luteinizing hormone by inhibition of pituitary function. Studies also suggest that the Megesterol's 
weight gain effect is related to its appetite-stimulant or metabolic effects rather than its 
glucocorticoid-like effects or the production of edema. It has also been suggested that Megesterol 
may alter metabolic pathyways via interferences with the production or action of mediators such 
as cachectin, a hormone that inhibits adipocyte lipogenic enzymes. 
Pharmacodynamics of Megesterol Acetate 
Megesterol Megesterol acetate significantly increases both appetite and bodyweight. In doses 
ranging from 160 to 1600 mg/day, Megesterol acetate shown to stimulate appetite, increase 
caloric intake, induce a sense of wellbeing, and produce weight gain. Weight gain occurs 
predominantly in the form of fat, which is of fat, which is potentially beneficial because the 
caloric stores in fatty tissue provide more kilocalories per gram than similar amounts of either 
protein or carbohydrate (i.e. 9.0 kcal vs 4.0 kcal and 4.0 kcal, respectively). Fat also helps 
stabilize core body temperatures and protects bony tissue; for example, the fat pads in the hips 
can help protect debilitated patients from hip fractures secondary to falls. 
Pharmacokinetics of Megesterol Acetate 
Megesterol acetate is absorbed rapidly from the gastrointestinal tract. However, studies in 
patients given the oral suspension demonstrate considerable variability in the rate and degree of 
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absorption; a factor that may be more significant in patients receiving the tablet formulation. In 
some patients, absorption is slower, with the more sustained plasma drug levels seen in a 1-
compartment model. In others, absorption is rapid, with a 2-compartment-like elimination curve. 
Megesterol acetate is completely metabolized in the liver to free steroids and the metabolites  are 
conjugated with glucuronic acid. Metabolites account for only 5–8% of the administered dose, 
which is considered negligible. The major route of drug elimination in humans is renal. 
Indications and usage: 
Megesterol acetate tablets are indicated for the palliative treatment of advanced carcinoma of the 
breast or endometrium (i.e., recurrent, inoperable, or metastatic disease). It should not be used in 
lieu of currently accepted procedures such as surgery, radiation, or chemotherapy. 
Adverse reactions: 
Weight Gain 
Weight gain is a frequent side effect of Megesterol. This gain has been associated with increased 
appetite and is not necessarily associated with fluid retention. 
Thromboembolic Phenomena 
Thromboembolic phenomena including thrombophlebitis and pulmonary embolism (in some 
cases fatal) have been reported. 
Other Adverse Reactions 
Heart failure, nausea and vomiting, edema, breakthrough menstrual bleeding, dyspnea, tumor 
flare (with or without hypercalcemia), hyperglycemia, glucose intolerance, alopecia, 
hypertension, carpal tunnel syndrome, mood changes, hot flashes, malaise, asthenia, lethargy, 
sweating and rash. 
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2.1.2. SODIUM STARCH GLYCOLATE 
Synonyms:  Carboxymethyl starch, sodium salt, carboxymethylamylum natricum. 
Chemical Name and CAS Registry Number: Sodium carboxymethyl starch [9063-38-1]. 
Structural Formula:  
 
Functional Category: Tablet and capsule disintegrant. 
Description: Sodium starch glycolate is a white or almost white free-flowing very hygroscopic 
powder. 
Solubility: Practically insoluble in methylene chloride. It gives a translucent suspension in water. 
Stability and Storage Conditions: Tablets prepared with sodium starch glycolate have good 
storage properties. Sodium starch glycolate is stable although very hygroscopic, and should be 
stored in a well-closed container in order to protect it from wide variations of humidity and 
temperature, which may cause caking. The physical properties of sodium starch glycolate remain 
unchanged for up to 3 years if it is stored at moderate temperatures and humidity. 
Incompatibilities: Sodium starch glycolate is incompatible with ascorbic acid. 
Applications in Pharmaceutical Formulation or Technology: 
 Sodium starch glycolate is widely used in oral pharmaceuticals as a disintegrant in 
capsule and tablet formulations. 
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 It is commonly used in tablets prepared by either direct-compression or wet-granulation 
processes. The usual concentration employed in a formulation is between 2% and 8%, 
with the optimum concentration about 4%, although in many cases 2% is sufficient.  
 Disintegration occurs by rapid uptake of water followed by rapid and enormous swelling. 
 Although the effectiveness of many disintegrants is affected by the presence of 
hydrophobic excipients such as lubricants, the disintegrant efficiency of sodium starch 
glycolate is unimpaired. Increasing the tablet compression pressure also appears to have 
no effect on disintegration time. 
 Sodium starch glycolate has also been investigated for use as a suspending vehicle. 
 S 
2.1.3. MANNITOL 
Synonyms: Cordycepic acid; 421; D- mannitol; manna sugar, mannite  
Chemical name CAS Registry Number: D- mannitol. [69-65-8]  
Empirical formula: C6H14O6. 
Molecular weight: 182.17 
Structural formula: 
 
Description:  
 It is a hexahydric alcohol related to mannose and isomeric with 
sorbital Mannitol occurs as a white, odourless, crystalline powder or free flowing granules. It 
has a sweet taste approximately as sweet as glucose and half as sweet as sucrose and imparts a 
cooling sensation in mouth. Microscopically, it appears as orthorhombic needles when 
crystallized from alcohol. 
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Functional categories: Sweetening agent; tablet and capsule diluent; tonicity agent; vehicle 
(bulking agent) for lyophilized preparation. 
Solubility: It is soluble in alkalis, in ethanol (95%) 1 in 83 in ether practically insoluble in 
glycerin 1 in 18, water 1 in 5.5. 
Stability and storage: It is stable and should be stored in well closed container in a cool, dry 
place. 
Incompatibilities: Not reported in dry state 
Applications in Pharmaceutical Formulations or technology: 
 Mannitol is widely used in pharmaceutical formulations and food products. 
 In pharmaceutical preparations it is primarily used as a diluent (10–90% w/w) in tablet 
formulations, where it is of particular value since it is not hygroscopic and may thus be 
used with moisture-sensitive active ingredients. 
 Mannitol may be used in direct-compression tablet applications for which the granular 
and spray-dried forms are available, or in wet granulations. 
 Granulations containing mannitol have the advantage of being dried easily 
 Specific tablet applications include antacid preparations, glyceryl trinitrate tablets, and 
vitamin preparations. 
 Mannitol is commonly used as an excipient in the manufacture of chewable  tablet  
formulations because of its negative heat of solution, sweetness, and ‘mouthfeel’ 
 Mannitol  has  also  been  used  to  prevent  thickening  in  aqueous  antacid 
suspensions of  aluminum hydroxide (<7% w/v). It has been suggested as a plasticizer 
in soft-gelatin capsules, as a component of sustained-release tablet formulations, and as 
a carrier in dry powder inhalers. It is also used as a diluent in rapidly.  
Chapter 2                                                                                                                                        Drug Profile 
 
 Page 29 
 
  
2.1.4. CROSSPOVIDONE      
Synonyms:  Crospovidonum, crosslinked povidone, PVPP, Insoluble PVP Polyplasdone XL; 
Polyplasdone XL-10; polyvinylpolypyrrolidone. 
Chemical Name and CAS Registry Number: 
1-Ethenyl-2-pyrrolidinone homopolymer [9003-39-8] 
Empirical Formula and Molecular Weight 
(C6H9NO) n >10, 00, 000 
Structural Formula: 
 
Description:  
White, free flowing, compressible powder. A synthetic homopolymer of cross-linked N-vinyl-2-   
pyrrolidone. 
Solubility:  
 Practically insoluble in water, acids, alkalis, and all organic solvents. Hygroscopic. Swells 
rapidly in water. Rapidly disperses in water, but does not gel even after prolonged exposure. 
Functional Category: Super-disintegrant 
Pharmacopeial Specifications 
pH: pH (10% slurry): 5.0 – 8.0 
Typical Properties 
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Acidity/alkalinity: pH= 5.0–8.0 for a 10% w/v aqueous solution 
Applications in Pharmaceutical Formulation or Technology 
 Crospovidone is a water-insoluble tablet disintegrant and dissolution agent used at 2–5% 
concentration in tablets prepared by direct compression or wet- and dry-granulation 
methods. 
 Stabilizers for beer, vinegar, fruit and wine, prolonging the storage life. 
 Disintegrants and fillers in pharmaceutical tablets and capsules.  
 Detoxicants in detoxifiers or toxin absorbents.  
 Stabilizers for moisture sensitive active ingredients (e. G. Vitamins, enzymes). 
 Crospovidone can also be used as a solubility enhancer. 
 With the technique of co-evaporation, crospovidone can be used to enhance the solubility 
of poorly soluble drugs. 
 
2.1.5. TALC 
Synonyms: Hydrous magnesium calcium silicate, powdered talc. 
Chemical Name and CAS Registry Number: Talc [14807-96-6] 
Empirical Formula and Molecular Weight: Talc is a purified, hydrated, magnesium silicate, 
approximating to the formula, Mg6 (Si2O5)4(OH) 4. 
Functional Category: Anticaking agent; glidant; tablet and capsule diluent; tablet and capsule 
lubricant. 
Description: Talc is a very fine, white to grayish-white, odorless, impalpable, unctuous, 
crystalline powder. It adheres readily to the skin and is soft to the touch and free from grittiness. 
Stability and Storage Conditions: Talc is a stable material and may be sterilized by heating at 
1608C for not less than 1 hour. It may also be sterilized by exposure to ethylene oxide or gamma 
irradiation. Talc should be stored in a well-closed container in a cool, dry place. 
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Incompatibilities: 
Incompatible with quaternary ammonium compounds 
Applications in Pharmaceutical Formulation or Technology:  
 Talc was once widely used in oral solid dosage formulations as a lubricant and diluent. 
 It is widely used as a dissolution retardant in the development of controlled-release 
products. 
 Talc is also used as a lubricant in tablet formulations, in a novel powder coating for 
extended-release pellets, and as an adsorbant. 
 In topical preparations, talc is used as a dusting powder, although it should not be used to 
dust surgical gloves. 
 
2.1.6. SODIUM ACETATE: 
Synonyms: 
Acetic acid, sodium salt; E262; natrii acetas trihydricus; sodium ethanoate. 
Chemical Name and CAS Registry Number: 
Sodium acetate anhydrous [127-09-3], Sodium acetate trihydrate [6131-90-4] 
Empirical Formula and Molecular Weight 
C2H3NaO2 82.0 (for anhydrous) 
C2H3NaO23H2O 136.1 (for trihydrate) 
Structural Formula 
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Description 
Sodium acetate occurs as colorless, transparent crystals or a granular crystalline powder with a 
slight acetic acid odor. 
Functional Category 
Antimicrobial preservative, buffering agent, flavoring agent, stabilizing agent. 
Solubility  
Soluble 1 in 0.8 in water, 1 in 20 in ethanol (95%). 
Applications in Pharmaceutical Formulation or Technology 
 Sodium acetate is used as part of a buffer system when combined with acetic acid in 
various intramuscular, intravenous, topical, ophthalmic, nasal, oral, otic, and 
subcutaneous formulations. It may be used to reduce the bitterness of oral 
pharmaceuticals.  
 It can be used to enhance the antimicrobial properties of formulations; it has been shown 
to inhibit the growth of S. aureus and E. coli, but not C. albicansin protein hydrolysate 
solutions. 
 It is widely used in the food industry as a preservative.  
 Sodium acetate has also been used therapeutically for the treatment of metabolic acidosis 
in premature infants and in hemodialysis solutions. 
2.1.7. SODIUM BENZOATE: 
Synonyms 
Benzoic acid sodium salt; benzoate of soda; E211; natrii benzoas; natrium benzoicum; sobenate; 
sodii benzoas; sodium benzoic acid. 
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 Chemical Name and CAS Registry Number 
Sodium benzoate [532-32-1] 
Empirical Formula and Molecular Weight 
C7H5NaO2 144.1 
Structural Formula 
 
Description 
Sodium benzoate occurs as a white granular or crystalline, slightly hygroscopic powder. It is 
odorless, or with faint odor of benzoin and has an unpleasant sweet and saline taste. 
Functional Category 
Antimicrobial preservative, tablet and capsule lubricant. 
Solubility  
Soluble 1 in 1.8 in water, 1 in 75 in ethanol (95%). 
Applications in Pharmaceutical Formulation or Technology 
 Sodium benzoate is used primarily as an antimicrobial preservative in cosmetics, foods, 
and pharmaceuticals.  
 It is used in concentrations of 0.02–0.5% in oral medicines, 0.5% in parenteral products 
and 0.1–0.5% in cosmetics. 
 Sodium benzoate is used in preference to benzoic acid in some circumstances, owing to 
its greater solubility. 
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 Sodium benzoate has also been used as a tablet lubricant(1) at 2–5% w/w concentrations. 
Solutions of sodium benzoate have also been administered, orally or intravenously, in 
order to determine liver function. 
Stability and Storage Conditions 
Aqueous solutions may be sterilized by autoclaving or filtration. The bulk material should be 
stored in a well-closed container, in a cool, dry place. 
Incompatibilities 
Incompatible with quaternary compounds, gelatin, ferric salts, calcium salts, and salts of heavy 
metals, including silver, lead, and mercury. Preservative activity may be reduced by interactions 
with kaolin or non ionic surfactants. 
2.1.8. SODIUM CITRATE 
Synonyms: 
Citric acid trisodium salt; sodium citrate tertiary; trisodium citrate. 
Chemical Name and CAS Registry Number: 
Trisodium 2-hydroxypropane-1,2,3-tricarboxylate dehydrate [6132-04-3] 
Empirical Formula and Molecular Weight: 
C6H5Na3O7_2H2O 294.10 
Functional Category: 
Alkalizing agent; buffering agent; emulsifying agent; sequestering agent. 
Description: 
Sodium citrate dihydrate consists of odorless, colorless, monoclinic crystals, or a white 
crystalline powder with a cooling, saline taste. It is slightly deliquescent in moist air, and in warm 
dry air it is efflorescent. 
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Structural Formula: 
 
 
Solubility:  
Soluble 1 in 1.5 of water, 1 in 0.6 of boiling water, practically insoluble in ethanol (95%). 
Applications in Pharmaceutical Formulation or Technology: 
 Sodium citrate, as either the dihydrate or anhydrous material, is widely used in 
pharmaceutical formulations. 
 It is used in food products, primarily to adjust the pH of solutions.  
 It is also used as a sequestering agent.  
 The anhydrous material is used in effervescent tablet formulations. 
 Sodium citrate is additionally used as a blood anticoagulant either alone or in combination 
with other citrates such as disodium hydrogen citrate.  
 Therapeutically, sodium citrate is used to relieve the painful irritation caused by cystitis, 
and also to treat dehydration and acidosis due to diarrhea. 
 
2.1.9. MAGNESIUM STEARATE 
Synonyms 
Dibasic magnesium stearate; magnesium distearate; magnesia stearas; magnesium octadecanoate; 
magnesium salt; stearic acid, magnesium salt. 
Chemical Name and CAS Registry Number 
Octadecanoic acid magnesium salt [557-04-0] 
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Empirical Formula and Molecular Weight 
C36H70MgO4 591.24 
Structural Formula 
[CH3 (CH2)16COO]2 Mg 
Functional Category 
Tablet and capsule lubricant. 
 Applications in Pharmaceutical Formulation or Technology 
 Magnesium stearate is widely used in cosmetics, foods, and pharmaceutical formulations.  
 It is primarily used as a lubricant in capsule and tablet manufacture at concentrations 
between 0.25% and 5.0% w/w. It is also used in barrier creams 
Description 
Magnesium stearate is a very fine, light white, precipitated or milled, impalpable powder of low 
bulk density, having a faint odor of stearic acid and a characteristic taste. The powder is greasy to 
the touch and readily adheres to the skin. 
 
2.2. POLYETHYLENE GLYCOL (PEG) 6000: 
Synonyms 
Polyglycol, Polyethylene oxide, Polyoxy ethylene, PEG 6000 
Chemical Name and CAS Registry Number 
a-Hydro-o-hydroxypoly(oxy-1,2-ethanediyl) [25322-68-3] 
Empirical Formula and Molecular Weight 
H(OCH2CH2)nOH     6000 
 
Functional Category 
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Ointment base; plasticizer; solvent; suppository base; tablet and 
capsule lubricant. 
Structural Formula 
 
 
 
Description 
The USP32–NF27 describes polyethylene glycol as being an addition polymer of ethylene oxide 
and water. Polyethylene glycol grades 200–600 are liquids; grades 1000 and above are solids at 
ambient temperatures. Solid grades (PEG>1000) are white or off-white in color, and range in 
consistency from pastes to waxy flakes. They have a faint, sweet odor. Grades of PEG 6000 and 
above are available as free flowing milled powders. 
Solubility 
Solid polyethylene glycols are soluble in acetone, dichloromethane, ethanol (95%), and 
methanol; they are slightly soluble in aliphatic hydrocarbons and ether, but insoluble in fats, fixed 
oils, and mineral oil.  
Applications in Pharmaceutical Formulation or Technology 
 Polyethylene glycols (PEGs) are widely used in a variety of pharmaceutical formulations, 
including parenteral, topical, ophthalmic, oral, and rectal preparations.  
 Polyethylene glycol has been used experimentally in biodegradable polymeric matrices 
used in controlled-release systems. 
 Polyethylene glycol 6000 is listed as an ophthalmic demulcent active ingredient. 
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 Polyethylene glycols are stable, hydrophilic substances that are essentially nonirritant to 
the skin. 
 In solid-dosage formulations, higher-molecular-weight polyethylene glycols can enhance 
the effectiveness of tablet binders and impart plasticity to granules. 
 Polyethylene glycols can also be used to enhance the aqueous solubility or dissolution 
characteristics of poorly soluble com pounds by making solid dispersions with an 
appropriate polyethylene glycol. 
 Polyethylene glycol grades with molecular weights of 6000 and above can be used as 
lubricants, particularly for soluble tablets. 
 
2.2.1. MICRCRYSTALLINE CELLULOSE (AVICEL pH  102) 
Synonyms 
Avicel PH; Cellets; Celex; cellulose gel; hellulosum microcristall num; Celphere; Ceolus KG; 
crystalline cellulose. 
Chemical Name and CAS Registry Number 
Cellulose [9004-34-6] 
Empirical Formula and Molecular Weight 
         (C6H10O5)n ≈36 000 
          where n≈220. 
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Structural Formula 
 
Functional Category 
Adsorbent; suspending agent; tablet and capsule diluent; tablet disintegrant 
Description 
Microcrystalline cellulose is a purified, partially depolymerized cellulose that occurs as a white, 
odorless, tasteless, crystalline powder composed of porous particles. It is commercially available 
in different particle sizes and moisture grades that have different properties and applications. 
Applications in Pharmaceutical Formulation or Technology 
 Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a binder/diluent 
in oral tablet and capsule formulations where it is used in both wet-granulation and direct-
compression processes. 
 Enhance drug dissolution by speeding tablet disintegration. 
 Improves flow, better compressibility, Accommodation of moisture-sensitive actives. 
 Microcrystalline cellulose also has some lubricant and disintegrant properties that make it 
useful in tableting. 
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UREA 
Synonyms 
Biopure 100; Germall 115; imidazolidinyl urea; 1,10- methylenebis{3-[3-(hydroxymethyl)-2,5-
dioxo-4-imidazolidinyl] urea}. 
Chemical Name and CAS Registry Number 
N, N00-Methylenebis {N0-[3-(hydroxymethyl)-2, 5-dioxo-4-imidazolidinyl] urea} [39236-46-9] 
Empirical Formula and Molecular Weight 
C11H16N8O8 388.29 (for anhydrous) 
C11H16N8O8.H2O 406.33 (for monohydrate) 
Structural Formula 
 
 
 
Functional Category 
Antimicrobial preservative. 
Description 
Imidurea is a white, free-flowing odorless powder. 
Solubility  
Soluble in water and in glycerol, but insoluble in almost all organic solvents. 
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Incompatibilities 
Imidurea is incompatible with strong oxidants. It is compatible with other preservatives including 
sorbic acid and quaternary ammonium compounds. 
Applications in Pharmaceutical Formulation or Technology 
 Imidurea is a broad-spectrum antimicrobial preservative used in cosmetics and topical 
pharmaceutical formulations; typical concentrations used are 0.03–0.5% w/w.  
 It is effective between pH 3–9 and is reported to have synergistic effects when used with 
parabens. 
 It is used as hydrotropic agent. 
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 CHAPTER -3 
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enhancement: solid dispersion. Objective of this work is to improve the solubility and 
dissolution rate of poorly water soluble Aceclofenac by solid dispersion method followed by 
solvent evaporation method. And to compare effectiveness of hydrophilic polymer PVP-k30, 
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most common flavonoids reported to possess numerous pharmacological activities and shows 
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different solubilisation techniques like; hydrotropic solubilization, mixed hydrotropy and 
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application of different hydrotropic agents at their optimum concentration; thus decreases the 
chances of their own toxicity. Result concluded that the toxic level of hydrotropic agents was 
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does not require chemical modification of hydrophobic drugs, use of organic solvents, or 
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reacting starch with citric acid at elevated temperatures. It was insoluble in water and has 
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3), 1:3(SD-4) and 1:9(SD-5) and were evaluated for dissolution rate and efficiency. All the 
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properties. Current Pharma Research., Vol. 3(1), 2012, 735-749. 
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Glimepiride with SSG at different ratios were prepared by physical mixing, solvent 
evaporation and kneading methods. The rapid release of poorly soluble Glimepiride from 
solid dispersions was influenced by the proportion of polymer and the method employed for 
its preparation. Among the three methods employed solvent evaporation and kneading 
methods were found to be suitable for improving the dissolution rate of Glimepiride. All the 
tablet preparations containing diluents were found to release the drug in the order of DCP> 
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Yeole. Preparation and Characterization of Solid Dispersion Tablet of Furosemide with 
Crospovidone. This article investigates enhancement of the dissolution profile of furosemide 
using solid dispersion (SD) with crospovidone (CPV) by using kneading technique. 1:1 (w/w) 
and 1:2 (w/w) solid dispersions were prepared by kneading method using solvent water and 
ethanol in 1:1 ratio. Dissolution studies using the USP paddle method were performed for 
solid dispersions of furosemide at 37 ± 0.5oC and 50 rpm in simulated gastric fluid (SGF) of 
pH 1.2. Fourier transformer infrared (FTIR) spectroscopy, differential scanning calorimetry 
(DSC), and x-ray diffractometry (XRD) were performed to identify the physicochemical 
interaction between drug and carrier, hence its effect on dissolution. Tablets were formulated 
containing solid dispersion products and compared with commercial products. Tablets 
containing solid dispersion exhibited better dissolution profile than commercial tablets. 
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(Megace). The tablets were administered to 24 male subjects in a three-way cross-over study, 
balanced for sequence, with a week between administrations. The 40 mg tablets were 
administered q.i.d. at 08.00, 12.00, 18.00 and 22.00 h, while the 160 mg tablets were 
administered once at 08.00 h. Plasma samples were collected at appropriate times out to 96 h 
after administration and were analysed for Megesterol acetate with a validated high 
performance liquid chromatographic procedure. Based on the times to maximum plasma 
concentrations (2.5 to 2.8 h), the absorption rate constant was the same for each of the tablets. 
Relative to the 40 mg q.i.d. dose, the 160 mg regular and the 160 mg micronized tablets had 
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dissolution profile and oral bioavailability of Megesterol acetate (MA), solid dispersions of 
MA (MASDs) were formulated with copovidone and crystal sugar as a hydrophilic polymeric 
carrier and an inert core bead, respectively. Solvent evaporation method and fluidized bed 
coating technique were employed. MASDs were categorized as crystalline solid dispersion by 
the characterization of differential scanning calorimetry and X-ray diffraction. Dissolution of 
MASD was gradually increased up to 15 min, after which it reached a plateau. For the initial 
period, dissolution rates were in the decreasing order of MASD (1:2) ≥ MASD (1:1) > 
MASD (1:3) > MASD (1:5) > MASD (1:0.5) > MA powder. In the comparative 
pharmacokinetic study with Megace OS, a reference drug product, MASD (1:1) showed 
improved bioavailability of over 220% with 2-fold higher C(max) and 30% faster T(max). 
We conclude that MASD (1:1) is a good candidate for the development of oral solid dosage 
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3.11. Yellela S.R. Krishnaiah. Pharmaceutical Technologies for Enhancing Oral 
Bioavailability of Poorly Soluble Drugs, The oral bioavailability of BCS class II drugs with 
poor solubility and reasonable permeability is limited by drug dissolution step from drug 
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engineering, nanosizing, solid dispersion, cyclodextrins and other colloidal drug delivery 
systems with few relevant research reports. Journal of Bioequivalence & Bioavailability, 
Volume 2(2): 028-036 (2010). 
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are implicated with poor oral bioavailability due to poor drug solubility in aqueous 
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believed to involve stimulation of appetite by both direct and indirect pathways and 
antagonism of the metabolic effects of the principal catabolic cytokines. Because the 
bioavailability of Megesterol acetate directly affects its efficacy and safety, the formulation 
was refined to enhance its pharmacokinetics. 
3.14. Purwa Jain, Achhrish Goel, Shweta Sharma, Meghal Parmar:  Solubility 
Enhancement Techniques with Special Emphasis on Hydrotrophy; Solubility is one of the 
important parameter to achieve desired concentration of drug in systemic circulation for 
pharmacological response to be shown. Drug efficacy can be severely limited by poor 
aqueous solubility and some drugs also show side effects due to their poor solubility. There 
are many techniques which are used to enhance the aqueous solubility. The ability to increase 
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3.15. Soon Wook Hong, Bong Sang Lee1, Su Jun Park: Solid Dispersion Formulations of 
Megesterol Acetate with Copovidone for Enhanced Dissolution and Oral Bioavailability: In 
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solid dispersions of MA (MASDs) were formulated with Copovidone and crystal sugar as a 
hydrophilic polymeric carrier and an inert core bead, respectively. Solvent evaporation 
method and fluidized bed coating technique were employed. MASDs were categorized as 
crystalline solid dispersion by the characterization of differential scanning calorimetry and X-
ray diffraction. Arch Pharm Res 2011. 
3.16. Bhawana Kapoor, Ramandeep Kaur, Sukhdeep Kour: Solid Dispersion: An 
Evolutionary Approach for Solubility Enhancement of Poorly Water Soluble Drugs. Although 
the oral route of administration is the most common and preferred method of delivery due to 
convenience and ease of ingestion for many drugs it can be a tricky and inefficient mode of 
delivery for water-insoluble drugs with high permeability or Class II drugs in FDA’s 
Biopharmaceutical Classification System (BCS). Such drugs typically exhibit dissolution rate 
limited absorption resulting in poor bioavailability when delivering via the oral route. Solid 
dispersion is a competent approach to deal with drugs that suffer from dissolution-limited 
absorption. This strategy has proven to improve the bioavailability by dispersing the 
hydrophobic drug as very fine particles within hydrophilic matrix that results in increased 
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2012. 
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hormone-dependent cancer, mainly endometrial cancer and less commonly breast cancer. 
This drug is also used for symptom relief in anorexia-cachexia syndrome (ACS) patients.1 
This syndrome that occurs among other things in the advanced stage of cancer or in 
association with HIV infection, is characterized by weight and appetite loss, decline in 
muscle and adipose tissue mass, worsening of the performance status and decrease in the 
quality of life level (well-being). Pol Arch Med Wewn 2008. 
3.18. H B Muss, L D Case, R L Capizzi, M R Cooper, J Cruz: High- versus standard-dose 
Megesterol acetate in women with advanced breast cancer: a phase III trial of the Piedmont 
Oncology Association; One hundred seventy-two patients with advanced breast cancer were 
randomized to receive oral standard-dose Megesterol acetate (MA), 160 mg/d or high-dose 
MA, 800 mg/d. All but two patients had one prior trial of tamoxifen therapy for either 
metastatic disease (74%) or as adjuvant treatment (26%). Pre-treatment characteristics were 
similar for both arms. High-dose MA resulted in a superior complete plus partial response 
rate (27% v 10%, P = .005), time to treatment failure (median, 8.0 v 3.2 months, P = .019), 
and survival (median, 22.4 v 16.5 months, P = .04) when compared with standard-dose 
therapy. These differences remained significant after adjustment for other covariates. 
American Society of Clinical Oncology 1990. 
3.19. Robert A. Femia and Richert E. Goyet. The Science of Megesterol Acetate Delivery.  
Potential to Improve Outcomes in Cachexiate. Cachexia, usually defined as the loss of >5% 
of an individual’s baseline bodyweight over 2–6 months, occurs with a number of diseases 
that includes not only AIDS and advanced cancer but also chronic heart failure, rheumatoid 
arthritis, chronic obstructive pulmonary disease, Crohn disease, and renal failure. 
Progestogens, particularly Megesterol acetate, are commonly used to treat anorexia-cachexia. 
The mechanism of action of Megesterol is believed to involve stimulation of appetite by both 
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direct and indirect pathways and antagonism of the metabolic effects of the principal 
catabolic cytokines. Because the bioavailability of Megesterol acetate directly affects its 
efficacy and safety, the formulation was refined to enhance its pharmacokinetics. Such efforts 
yielded Megesterol acetate in a tablet form, followed by a concentrated oral suspension form, 
and an oral suspension form developed using nanocrystal technology. Nanocrystal 
technology was designed specifically to optimize drug delivery and enhance the 
bioavailability of drugs that have poor solubility in water. Biodrugs 2005; 19 (3): 179-187. 
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CHAPTER 4 
EXPERIMENTAL WORK 
 
4.1: Materials used in the present research work. 
Table No: 2   List of Materials 
 S.No  Name of the product Name of the supplier 
1 Megesterol acetate  Natco Pharma Pvt,Ltd.Hyderabad 
2 PEG 6000 Finar chemicals limited,Ahmedabed 
3 Sodium starch glycolate Finar chemicals limited,Ahmedabed 
4 Avicel pH 102 Natco Pharma Pvt,Ltd.Hyderabad 
5 CrosspovidoneXL10 Natco Pharma Pvt,Ltd.Hyderabad 
6 Mannitol Finar chemicals limited,Ahmedabed 
7 Urea Finar chemicals limited,Ahmedabed 
8 Sodium benzoate Finar chemicals limited,Ahmedabed 
9 Sodium acetate Finar chemicals limited,Ahmedabed 
10 Sodium citrate Finar chemicals limited,Ahmedabed 
11 Acetonitrile Finar chemicals limited,Ahmedabed 
12 Talc Reidel (India) Chemicals, Hapur 
13 Magnesium stearate S.D.Fine-chem limited, Mumbai 
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4.2 Table 3: List of Equipments and Instruments used 
S.No. EQUIPMENTS SOURCE 
1  U.V/Visible spectrophotometer  Elico SL 159 
2 Electronic Balance Sartorius, German. 
3 
 Rotary tablet compression machine   
 
Cadmach, Ahmadabad. 
4 Disintegration test apparatus Electro Lab (ED-2L) Kshitij 
5 pH Meter (pH 510)  Systronic, µ pH system 365 
6 USP Dissolution test apparatus XXIII 
 VEGO Disso 2000, Navi, 
Mumbai 
7 Friabilator  Cintex,Mumbai 
8 
Hot Air Oven(temperature controlled µp 
Based 
Servewell Inst rument  P v t , 
L t d ,  I n d i a . 
9 Melting point apparatuses Cintex , Mumbai 
10 Stability Chamber 
Labtop InstrumentPvt, Ltd, 
Bangalore. 
11 Micro pippette’s(100-1000µl) Brand, German. 
12 Hardness Tester Monsanto, Mumbai. 
13 Tap Density Apparatus Campbell electronics, Mumbai. 
14 FTIR Jasco FTIR 6100 type-A, Japan. 
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4.3PREFORMULATION STUDIES: 
Preformulation studies are the first step in the rational development of dosage form of 
a drug substance. Preformulation can be defined as investigation of physical and chemical 
properties of drug substance alone and when combined with excipients. 
4.3.1Organoleptic characteristics:  
The colour, odour, and taste of the drug were characterized and recorded using descriptive 
terminology. 
Table 4: Organoleptic properties 
Colour Odour Taste 
Off white Pungent Acidic 
Cream white Sulfurous Bitter 
Tan Fruity Bland 
Shiny Aromatic Intense 
 Odorless Sweet 
  Tasteless 
 
4.3.2Melting point depression 
A characteristic of a pure substance is defined by its melting point or melting range. If not 
pure, the substance will exhibit a change in melting point. This phenomenon is commonly 
used to determine the purity of a drug substance and sometimes compatibility of various 
substances. It is Determined by Capillary method is using Melting point apparatus. 
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4.3.3SOLUBILITY DETREMINATION:  
Solubility of Megesterol acetate was determined in ethanol, water and acetone. Solubility 
studies were performed by taking excess amount of Megesterol acetate in different beakers 
containing solvent. The mixtures were shaken for 24 hrs at regular intervals. The solutions 
were then filtered by using Whatmann’s filter paper. The filtered solutions are analyzed 
spectrophotometrically. 
                   Table 5: Solubility chart 
         Descriptive term Approximate  volume   
 Very soluble 
Freely soluble 
Soluble 
Sparingly soluble 
Slightly soluble 
Very slightly soluble 
Practically insoluble 
Less than 1 
From 1 to 10 
From 10 to 30 
From 30 to 100 
From 100 to 1000 
From 1000 to 10,000 
             More than 10,000 
  
4.3.4 MICROMERITIC PROPERTIES: 
4.3.4.1 PARTICLE SHAPE & PARTICLE SIZE: 
Bulk flow, formulation homogeneity, and surface-area controlled processes such as 
dissolution are directly affected by size, shape and surface morphology of the drug particles.  
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    Fig 9: Particle shape                                 Table: 6 Particle size range 
 
4.3.4.2 MICROSCOPY:  
Optical microscopy is generally used as the first tool to see and measure sizes of 
particles ranging in size from 0.2 microns to 100 microns. 
4.3.4.3 PARTITION COEFFICIENT (PO/W): 
 Partition coefficient (oil/water) is a measure of a drug's lipophilicity and an indication of its 
ability to cross cell membranes. It is defined as the ratio of un-ionized drug distributed 
between the organic and aqueous phases at equilibrium. The partition coefficient is commonly 
determined using an oil phase of octanol or chloroform and water.  
 
 
 
TECHNIQUE SIZE 
RANGE 
Microscopic 1 – 100 
Sieve > 50 
Sedimentation > 1 
Elutriation 1 – 50 
Centrifugal < 50 
Permeability > 1 
Light scattering 0.5 – 50 
                           Po/w = (Coil/Water) equilibrium  
     P value >1 –lipophilic drug, P value <1-hydrophilic drug  
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4.3.4.4 BULK DENSITY (Db): 
It is the ratio of total mass of powder to the bulk volume of powder. It was measured 
by pouring the weighed powder (passed through standard sieve # 20) into a measuring 
cylinder and initial weight was noted. This initial volume was called the bulk volume. It is 
expressed in gm/ml and is given by 
  
 
 
4.3.4.5 TAPPED DENSITY (Dt): 
It is the ratio of total mass of the powder to the tapped volume of the powder. Volume 
was measured by tapping the powder for 750 times and the tapped volume was noted if the 
difference between these two volumes is less than 2%. If it is more than 2%, tapping is 
continued for 1250 times and tapped volume was noted. Tapping was continued until the 
difference between successive volumes is less than 2% (in a bulk density apparatus). It is 
expressed in gm/ml and is given by 
 
 
4.3.4.6 ANGLE OF REPOSE (Θ): 
The friction forces in a loose powder can be measured by the angle of repose (θ). It is 
an indicative of the flow properties of the powder. It is defined as maximum angle 
possible between the surface of the pile of powder and the horizontal plane. 
                               M is the mass of powder 
          Vb is the bulk volume of the powder. 
Db= M/Vb 
                                M is the mass of powder 
          Vb is the tapped volume of the powder. 
Dt = M/Vt 
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The powder mixture was allowed to flow through the funnel fixed to a stand at define height 
(h). The angle of repose was then calculated by measuring the height and radius of the heap of 
powder formed.  
  Table 7 Angle of Repose as an Indication of Powder Flow Properties 
Sr.No. Angle of Repose (θ)  Type of Flow 
1 <20 Excellent 
2 20 – 30 Good 
3 30 – 34 Passable 
4 > 34 Very Poor 
 
4.3.4.7 CARR’S INDEX (OR) % COMPRESSIBILITY: It indicates powder flow 
properties. It is expressed in percentage and is given by 
          Dt – Db 
    I = ---------------- x 100 
                 Dt 
     Where, Dt is the tapped density and Db is the bulk density of the powder. 
 
 
 
Where, θ is the angle of repose 
                                                      h is the height in cm & r is the radius in cm 
  Tan (θ) = h/r 
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       Table 8: Relationship between % compressibility and flow ability 
 
 
4.3.4.8 HAUSNER’S RATIO: Hausner’s ratio is an indirect index of ease of powder flow. It 
was calculated by the following formula. 
 
  
Table 9: Hausner’s ratio 
. 
 
 
 
 
 
% Compressibility Flow ability 
5 -12  Excellent 
12 – 16 Good 
18 – 21 Fair Passable 
23 – 35 Poor 
33 – 38 Very Poor 
< 40 Very Very Poor 
Flow Characteristics  Hausner’s Ratio 
Excellent -no arching, Flow aid not needed 1.00-1.11 
Good-aid not needed will not arch 1.12-1.18 
Fair-Vibration may be needed 1.19-1.25 
Passable-borderline, material may hang up 1.26-1.34 
Poor-must agitate, vibrate 1.35-1.45 
Very poor-requires agitation 1.46-1.59 
Very very poor-special, agitation of hoper 
required >1.60 
                                                          Dt is tapped density 
                                                          Db is bulk density 
Hausner’s ratio= Dt/Db 
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4.3.5 HYGROSCOPICITY (%H):  
The hygroscopicity of a powder is its equilibrium moisture content after being 
exposed to air humidity under given conditions. It was determined by calculating the increase 
in sample weight after being kept in a humidifier at ambient relative humidity of 76 ±2% and 
a temperature of 22± 20C for 24 h. 
Procedure: The saturated solution of Ammonium chloride / Ammonium sulfate was prepared 
and sample of 50 ml was taken in a dessicator to maintain humidity of 75 ±2%. 
  Weight of empty stoppered Petri plate is m1 
  Weight of empty stoppered Petri plate + drug sample is m2 
The petri plate is unstoppered and placed in dessicator containing Ammonium chloride 
solution and kept for 24 hrs. 
         Weight of empty stoppered Petri plate + drug sample after 24 hrs is m3 
               
                          
Table 10: HYGROSCOPICITY 
         HYGROSCOPICITY             WEIGHT  GAIN 
Slight hygroscopic 0.0 -0.12% 
Hygroscopic 0.12 -2% 
Very hygroscopic 2- 15% 
Deliquescent >15% 
 
    m3 – m2/ m2 – m1 *100 
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4.3.6 STABILITY STUDIES: 
4.3.6.1 FT-IR SPECTRAL STUDIES: 
The IR spectra for the formulation excipients and pure drugs were recorded on FTIR 
spectrophotometer using KBr palette technique (1:100) at the resolution rate of 4cm-1. 
Spectrum was integrated in transmittance mode at the wave number range 400-4000 cm-1 
4.3.6.2 MICROBIOLOGICAL GROWTH STUDY OF ALL POLYMERS AND 
DRUGS: 
100 mg of the polymer sample were separately aseptically mixed with 9 ml of sterile normal 
saline and the PH was adjusted to 7. 1ml of dispersion was mixed with 20 ml of sterile lactose 
broth and placed separately in Petri dish. And the plates were incubated at 37±1oC for 24 hr. 
After incubation period the samples were observed for the presence of micro flora. 
4.3.6.3 Thermal stability 
Megesterol acetate powder was exposed to different temperature in an oven for 24 h. 
Table 11 Thermal stability 
S.No Temperature 
1 00c 
2 100c 
3 200c 
4 300c 
5 400c 
6 500c 
7 600c 
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4.3.7ANALYTICAL METHOD DEVELOPMENT: 
 Megesterol acetate can be estimated by various methods such as HPTLC, UV 
spectrophotometry, HPLC etc. In the present investigation, Megesterol acetate was estimated 
by UV/VIS spectrophotometer. 
4.3.7.1 Preparation of stock solution: 
Megesterol acetate (25mg) was accurately weighed and transferred into the 25 ml volumetric 
flask. It was dissolved in acetonitrile and volume was made up to the mark with acetone to get 
a 1000 ug/ml solution (Stock A). From this 1 ml was pipette out and then diluted up to 100 ml 
with 1% SLS to get a stock solution of 10µg/ml (Stock B). 
From the stock B solution 2, 4, 6,8and 10 ml were transferred to 10 ml volumetric 
flasks and diluted with the 1% SLS, up to the mark to obtain Megesterol acetate concentration 
of 2, 4,6,8and 10µg/ml respectively. 
4.4 FORMULATION DEVELOPMENT OF MEGESTEROL ACETATE: 
4.4.1.1. Solid dispersion of Megesterol acetate with PEG 6000 by solvent evaporation 
tehnique:  
This method involves dissolving drug and carrier in a common organic solvent and then 
evaporating the solvent, the carrier taken is PEG 6000.  The solid dispersions are prepared by 
solvent evaporation at weight ratios 1:1, 1:2, 1:3, 1:4, 1: 5 for megesterol and PEG 6000. The 
appropriate amount of megesterol and PEG 6000 were dissolved in acetonitrile with continous 
stirring. Than the solvent was evaporated at ambient temperature and kept in dessicator for 24 
hrs, then powdered in a mortar and sieved through 60 mesh screen and stored at ambient 
temperature for further use.  
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Table 12 Composition of solid dispersion of megesterol acetate with PEG 6000: 
S. No Megesterol : PEG 6000 Batch code 
1 1:1 SP1 
2 1:2 SP2 
3 1:3 SP3 
4 1:4 SP4 
5 1:5 SP5 
 
4.4.1.2. Formulation of megesterol acetate tablets using superdisintegrants by Direct 
Compression: 
1. Weighing & Sifting: Solid dispersion, superdisintegrants (sodium starch glycolate, 
cross povidone XL10) and all other ingredients except lubricants were accurately 
weighed and sifted through # 40 mesh. 
2. Mixing and blending: Step 1 materials were mixed and blended in a mortar. 
3. Lubrication: Talc, magnesium stearate was accurately weighed and sifted through 
#60 mesh. Step 2  materials were blended with  lubricants for 2 min. 
4. Compression: The final blend was compressed into tablets with 7.5mm tooling set 
Table13: Composition of Megesterol acetate with PEG6000 by dry granulation technique 
Super Disintegrants   Sodium starch glycolate  Crosspovidone XL10 
Formula F1mg  F2mg F3mg F4mg F5mg F6mg F7mg F8mg 
Solid dispersion SP1 
(40) 
SP2 
(60) 
SP3 
(80) 
SP4 
(100) 
SP5 
(120) 
SP1 
(40) 
SP2 
(60) 
SP3 
(80) 
SSG 9 9 9 9 9 -- -- -- 
CrosspovidoneXL10 -- -- -- -- -- 9 9 9 
Mannitol 18.75 18.75 18.75 18.75 18.75 18.75 18.75 18.75 
Avicel pH 102 227.75 207.75 187.75 167.75 147.75 227.75 207.75 187.75 
Talc  3 3 3 3 3 3 3 3 
Mg. stearate 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
Total weight 300 300 300 300 300 300 300 300 
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4.4.2. Hydrotropic approach: 
Initially solubility of Megesterol acetate was determined individually in solutions of 4 
hydrotropic agents (Ha) namely urea (U), sodium acetate (A), sodium benzoate (B), sodium 
citrate (C) at concentration of 10%, 20%, 30% and 40% solutions using purified water as 
solvent. For determining solubility, accurately measured 3 ml of particular hydrotropic agent 
was taken in a 10 ml volumetric flask and excess amount of drug was added and mechanically 
shaken until saturated solution was formed. The volumetric flask was shaken on mechanical 
shaker for 12 h so that equilibrium solubility can be achieved and solution was allowed to 
equilibrate for 24 h. Then solution was centrifuged at 2000 rpm for 5 min in ultra-centrifuge 
and then solution was filtered through whatmann’s grade 41 filters. Aliquot was suitably 
diluted with purified water and analyzed using UV spectrophotometer at 292 nm. 
Table 14: composition of hydrotropic agents 
Ingredients formulation concentration 
  
  
Sodium acetate 
F9 10% 
F10 20% 
F11 30% 
F12 40% 
  
  
Sodium benzoate 
F13 10% 
F14 20% 
F15 30% 
F16 40% 
  
  
Sodium citrate 
F17 10% 
F18 20% 
F19 30% 
F20 40% 
  
  
Urea 
F21 10% 
F22 20% 
F23 30% 
F24 40% 
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4.4.2.1Mixed Hydrotropy: 
Table 15: composition of hydrotropic agents in combination 
Ingredients Sodium 
acetate 
Sodium 
benzoate 
Sodium 
citrate 
Urea Total % 
F25 20 -- -- 20 40% 
F26 -- 20 -- 20 40% 
F27 -- -- 20 20 40% 
F28 20 20 -- -- 40% 
F29 20   20   40% 
F30   20 20 -- 40% 
F31 5% 15% 20% -- 40% 
F32 15% 20% 5% -- 40% 
F33 20% 5% 15% -- 40% 
F34 10% 10% 20% -- 40% 
F35 10% 20% 10% -- 40% 
F36 20% 10% 10% -- 40% 
F37 -- 15% 20% 5% 40% 
F38 -- 20% 5% 15% 40% 
F39 -- 5% 15% 20% 40% 
F40 -- 10% 20% 10% 40% 
F41 -- 20% 10% 10% 40% 
F42 -- 10% 10% 20% 40% 
  
 
4.4.2.2. Preparation of solid dispersions of Megesterol Acetate with hydrotropic agents 
by physical mixing method: 
For preparation of solid dispersion with optimized hydrotrope concentration, 
accurately weighed Urea, sodium benzoate, sodium citrates were taken in a mortar and were 
mixed properly, then megesterol acetate was added to the above blend and thoroughly 
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triturated for 5min. The solid dispersion thus obtained was passed through sieve # 60 and 
were finally stored in an airtight glass bottle. 
 Table 16: composition of solid dispersion of Megesterol acetate and hydrotropic agents 
            Drug                      Hydrotropic agents 
Megesterol Acetate Urea Sodium benzoate Sodium acetate 
Equivalent wt 20 mg 10% 10% 20% 
  
 
4.5-Pre compression studies: 
4.5.1-Angle of Repose: 
The angle of repose of granules was determined by the funnel method. The accurately 
weighed granules/ powder were taken in a funnel. The height of the funnel was adjusted in 
such a way that the tip of the funnel just touched the apex of the heap of the granules. The 
granules were allowed to flow through the funnel freely onto the surface. The diameter of the 
powder cone was measured and angle of repose was calculated using the following equation: 
                                                      tan θ = h/r (1) 
               Where h and r are the height and radius of the powder cone. 
4.5.2-Bulk Density & Tapped density: 
Both loose bulk density (LBD) and tapped bulk density (TBD) were determined. A quantity 
of 1g of powder from each formula, previously lightly shaken to break any agglomerates 
formed, was introduced into a 10 ml measuring cylinder. After the initial volume was 
observed, the cylinder was allowed to fall under its own weight onto a hard surface from the 
height of 2.5 cm at 2-second intervals. The tapping was continued until no further change in 
volume was noted. LBD and TBD were calculated using the following formulas. 
                       LBD = weight of the powder/volume of the packing (2) 
                      TBD = weight of the powder/ tapped volume of the packing (3) 
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4.5.3. Compressibility Index: 
Compressibility index of the granules was determined by Carr’s compressibility index  
                           Carr’s Index (%) = [(TBD-LBD) × 100] / TBD 
4.5.4. Drug content evaluation: 
100 mg equivalent weight of sample was weighed and add suitable medium and made up to 
100 ml with medium. 1ml of this solution is made up to 100 ml with buffer. Drug content was 
estimated by an UV spectrophotometric method based on the measurement of absorbance at 
particular nm. 
4.6-Evaluation of tablets: 
4.6.1-Weight variation: 
Twenty tablets were weighed individually and the average weight was determined. Then 
percentage deviation from the average weight was calculated. Deviation should not exceed the 
values given in table 
 
Table 17: Standard limit value in weight variation test 
Average weight of a tablet Percentage Deviation 
 
80 mg or less ±10 
 
>80 and <250mg ±7.5 
 
250mg or more ±5 
 
 
4.6.2-Hardness: 
Hardness indicates the ability of a tablet to withstand mechanical shocks while handling the 
hardness of the tablets was determined using Pfizer hardness tester. It is expressed in kg/cm2. 
Three tablets were randomly picked and hardness of the tablets was determined. 
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4.6.3-Friability: 
Roche Friabilator was used for testing the friability. Twenty tablets were weighed accurately 
and placed in the tumbling apparatus that revolves at 25 rpm. After 4 min., the tablets were 
weighed and the percentage loss in tablet weight was determined.   
                                   Initial wt. of tablets - Final wt. of tablets 
                     % loss = ---------------------------------------------------- x 100 
                                                       Initial wt. of tablets 
4.6.4-Tablet thickness: 
Thickness was measured using a calibrated screw gauge. Three tablets of each formulation 
were picked randomly and thickness was measured individually. 
4.6.5. In Vitro Disintegration Test 
The test was carried out on 6 tablets using digital tablet disintegration tester (Veego, India). 
1% SLS solution at 37°C ± 2°C was used as a disintegration media, and the time taken for 
complete disintegration of the tablet with no palpable mass remaining in the apparatus was 
measured in seconds. 
4.6.6. Wetting Time 
A Petri dish containing 6 ml of distilled water was taken. A tablet containing a small quantity 
of amaranth color was placed on it. Time required for the upper surface of the tablet to 
become complete red was noted. 
 
4.6.7-Drug content: 
Ten tablets were weighed and powdered and required mg equivalent weight of drug was 
accurately weighed and transferred into a 100 ml volumetric flask. It was dissolved and made 
up the volume with medium. Subsequently the solution in volumetric flask was filtered and 
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suitable dilutions were made and analyzed at particular nm using UV-Visible 
spectrophotometer. The drug content of each sample was estimated from standard curve of 
drug using particular medium. 
4.6.8-In vitro drug release: 
The USP paddle method was adopted in this study. The release medium consisted of 900 ml 
of 1% SLS. A known quantity from each batch of the Megesterol acetate were placed in 
appropriate chamber of the release apparatus and agitated at 50 rpm. At predetermined time 
intervals, 10 ml of the release medium was withdrawn, appropriately diluted and absorbance 
determined at a wavelength of 249 nm using UV spectrophotometer. The volume of the 
release medium was kept constant by replacing it with 10ml of fresh buffer medium after each 
withdrawal.  
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CHAPTER 5 
INVESTIGATIONAL REPORTS 
  
5.1 PRE-FORMULATION STUDIES: 
5.1.1 Identification of Megesterol Acetate:  
                                                                                                                                      
PARAMETRE STANDARD VALUE OBSERVED VALUE 
Description Crystalline powder Crystalline powder 
Odor Odor  less Odor  less 
Colour White White 
Solubility 
Practically insoluble in water, 
sparingly soluble in alcohol; 
soluble in acetone; very soluble 
in chloroform 
Practically insoluble in water, 
sparingly soluble in alcohol; 
soluble in acetone; very soluble 
in chloroform 
Melting point 213-220 oC 214 oC 
Percentage purity 99% 98.9% 
Table  18: Identification of Megesterol Acetate 
 
 
5.1.2. Thermal degradation: 
 
Temperature  Initial concentration  Concentration after 3 hr 
40˚C 0.3291 0.430 
60˚C 0.3291 0.191 
Table no.19.  Thermal degradation 
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    5.1.3. Flow properties of Megesterol Acetate: 
 
 
 
Table  20: Flow properties of Megesterol Acetate 
5.1.4. Solubility of API in different solvents 
Solubility of API (%)  
Time 
Intervals 
(nm) 
Water + 0.5% 
SLS 
 Water + 1% 
SLS 
pH 1.2 (USP) + 
1% SLS  
pH 4.5 (USP) + 
1% SLS  
15 46.1 74.8 60.7 75.6 
30 58.5 84.1 70.7 99.6 
60 60.9 93.7 83.6 - 
120 63.5 - 88.8 - 
Table:21 Solubility of API in different solvents 
5.1.5 Partition Co-efficient: 
The Partition Co-efficient value obtained from hexane to water is 4.569 
5.1.6.  Hygroscopicity:  
It is evident by no change in the weight of the sample at higher moisture level of 75% RH even 
after 168 hrs and at the same time powder  is not stick to the Petri dish and is free flowing. 
PARAMETRE OBSERVED VALUE 
Angle of repose 31.370 
Bulk density 0.386 gm/cc 
Tapped density 0.678 gm/cc 
Cars index % 43.103 % 
Hausner‘s ratio 1.75 
Drug content 97% 
Particle Shape & Size Cube shape crystals, 15.29 um 
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Table 22: Hygroscopicity of Megesterol acetate 
Temp / Humidity Observation after 168 hrs Megesterol acetate 
(API) 
25oC  / 29 RH % Moisture pick up (Maximum) 0.175 
25oC  / 43 RH % Moisture pick up (Maximum) 0.238 
25oC  / 75 RH % Moisture pick up (Maximum) 0.085 
 
5.2. MICROBIAL TESTING OF DRUG AND POLYMERS: 
 
 
 
 
 
 
 
 
Fig: 3  Megesterol Acetate                                    Fig : 4  Megesterol Acetate with PEG 6000 
 
 
 
 
 
 
 
Fig: 5  Megesterol with SSG                            Fig : 6 Megesterol with Crosspovidone XL10     
 Microbial testing of drug and polymer                     
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5.3 ANALYTICAL METHOD DEVELOPMENT 
           5.3.1. Analytical methods for estimation of Megesterol acetate by  
                        UV/VIS Spectrophotometer        
Concentration(X) 
(µg / ml) 
Absorbance (Y) 
2 0.170 
4 0.368 
6 0.543 
8 0.729 
10 0.891 
Table 23: Analytical methods for estimation of Megesterol acetate 
            5.3.2.  Standard Calibration Curve of Megesterol acetate: 
 
Fig no: 7 Standard Calibration Curve of Megesterol acetate  
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5.4. STABILITY STUDIES 
               FT IR Spectral studies: 
Fig no. 8 IR Studies of Megesterol acetate  
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                                       Fig no.9 IR Studies of Drug + PEG 6000 
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                                   Fig no.10 IR Studies of Drug + Avicel pH 102 
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Fig no.11 IR Studies of Drug + sodium acetate 
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Fig no.12 IR Studies of Drug + sodium benzoate 
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Fig no.13  IR Studies of Drug + sodium citrate 
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5.5. EVALUATION OF PRE- COMPRESSION PARAMETRES: 
Tabl e 24: Characterization of Megesterol Acetate powder Formulated with Citric acid:  
Table 25: Post compression studies of Megesterol Acetate tablets  with Superdisintegrants:  
Formula Angle of                   
repose      
BD (g/cc) TD (g/cc) Carr’s index 
(%)   
Hausners 
ratio 
Drug 
content (%) 
F1 25.40 0.68 0.72 9.55 1.15 97.5 
F2 25.50 0.67 0.710 9.6 1.17 95.5 
F3 25.20 0.64 0.708 8.5 1.06 96.5 
F4 24.40 0.62 0.690 10.1 1.058 98.2 
F5 26.40 0.68 0.732 9.1 1.09 97.5 
F6 24.50 0.60 0.71 10.8 1.09 95.5 
F7 23.20 0.69 0.75          11.1 1.18 96.5 
F8 23.40 0.70 0.74 11.4 1.20 98.2 
Formulation F1 F2 F3 F4 F5 F6 F7 F8 
Hardness 
(kg/cm2) 
4.5±1.0 4.5.0±1.0
2 
4.0±1.02 4.5±1.0
8 
4.0±1.0
2 
4.5±1.0
2 
4.0±1.0 4.5±1.0
2 
Friability 
(%) 
0.62±0.0
1 
0.55±0.0
2 
0.58±0.0
1 
0.55±0.
05 
0.60± 
0.01 
0.65±0.
02 
0.59±0.
01 
0.52±0.
02 
Weight 
Variation 
(mg) 
298±0.7 299±0.5 299±0.8 
298.5±
0.2 
299±0.
1 
298.7±
0.2 
299.2±
0.1 
298.9±
0.7 
Thickness 
(mm) 
2.60 2.3 2.4 2.35 2.4 2.42 2.38 2.4 
Drug 
Content 
96.5±0.2 97±0.5 97.8±0.6 98±0.5 97±0.5 
98.9±0.
2 
98±0.5 
98.5±0.
1 
Disintegratio
n time (sec) 
65±0.6 62±0.4 75±0.2 76±0.4 82±0.2 54±0.7 42±0.2 
34±0.5 
 
Wetting 
time(sec) 
214±0.9 175±0.85 57±1.04 49±0.5 46±0.6 35±1.0 42±0.2 34±0.5 
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Table no. 26. Dissolution studies of Megesterol acetate with SSG &Crosspovidone 
Time 
(min) 
                                 % Drug release in the formulations 
                             Sodium Starch Glycolate       Crosspovidone 
Puredrug F1 
(1:1) 
F2 
(1:2) 
F3 
(1:3) 
F4 
(1:4) 
F5 
(1:5) 
F6 
(1:1) 
F7 
(1:2) 
F8 
(1:3) 
0 0 0 0 0 0 0 0 0 0 
10 2.13 10.8 12.9 16.75 13.1 12.8 26.2 18.85 17.5 
20 3.5 27.8 23.6 32.39 26.2 22.8 95.8 72.5 73.6 
30 4.77 40.17 36.6 58.9 49.4 38.13  90.2 80.2 
40 6.54 48.8 47.9 79.55 69.6 47.02   82.5 
50 6.8 66.1 73.8 89.9 78.5 71.6   85.8 
60 6.48 78.5 85.6.5  87.9 86.5    
 
 
 
Fig no. 14 drug release profile of Megesterol tablets with SSG 
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Fig no. 15 drug release profile of Megesterol tablets with Crosspovidone 
 
5.5.1. First order graph of Megesterol tablets with SSG 
 
Fig no.16 First order graph of Megesterol tablets with SSG 
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5.5.2. First order graph of Megesterol tablets with Crosspovidone 
 
                          Fig no. 17. First order graph of Megesterol tablets with Crosspovidone 
5.6. HYDROTROPY: 
           Table no. 27. Solubility studies of Megesterol with different Hydrotropic agents 
Ingredients formulation concentration Solubility in mg/ml 
 
Sodium acetate 
F9 10% 0.00439 
F10 20% 0.00491 
F11 30% 0.00541 
F12 40% 0.00849 
 
Sodium benzoate 
F13 10% 0.029 
F14 20% 0.0472 
F15 30% 0.079 
F16 40% 0.98 
 
Sodium citrate 
F17 10% 0.00826 
F18 20% 0.446 
F19 30% 0.544 
F20 40% 0.886 
 
Urea 
F21 10% 0.0098 
F22 20% 0.011 
F23 30% 0.039 
 F24 40% 0137 
y = -0.0089x + 1.9858
R² = 0.99
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5.6.1. Mixed hydrotropy: 
Table. 28. Solubility studies of Megesterol with different Hydrotropic agents in combination 
Ingredie
nts 
Sodium 
acetate 
Sodium 
benzoate 
Sodium 
citrate 
Urea Total % Solubility 
in mg/ml 
F25 20 -- -- 20 40% 0.0174 
F26 -- 20 -- 20 40% 0.0182 
F27 -- -- 20 20 40% 0.0914 
F28 20 20 -- -- 40% 0.195 
F29 20  20  40% 0.0176 
F30  20 20 -- 40% 0.222 
F31 5% 15% 20% -- 40% 0.639 
F32 15% 20% 5% -- 40% 1.143 
F33 20% 5% 15% -- 40% 0.3358 
F34 10% 10% 20% -- 40% 1.195 
F35 10% 20% 10% -- 40% 0.242 
F36 20% 10% 10% -- 40% 0.347 
F37 -- 15% 20% 5% 40% 6.099 
F38 -- 20% 5% 15% 40% 1.0806 
F39 -- 5% 15% 20% 40% 1.004 
F40 -- 10% 20% 10% 40% 9.14 
F41 -- 20% 10% 10% 40% 6.96 
F42 -- 10% 10% 20% 40% 0.688 
F43 10 10 10 10 40% 1.008 
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5.6.2. Drug release profile of Megesterol acetate tablets using hydrotropic 
agents: 
 
Table no. 29.% of drug release of Megesterol acetate tablets using hydrotropic agents 
Time 
(min) 
% Drug release 
 
F16(B) 
 
F30(A+B) 
 
 
F34(A+B+C) 
 
 
F40(U+B+C) 
 
10 9.87 13.75 22.40 36.71 
20 14.34 21.32 35.93 98.34 
30 22.90 38.02 52.06 103.06 
40 39.21 42.21 70.32  
50 56.86 65.84 98.21  
60 68.93 78.23 102.3  
          
 
 
                  Fig no. 18. Drug release profile of Meg. Acetate tablets with hydrotropic agents 
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 5.6.3. First order graph of Megesterol tablets with hydrotropic agents 
 
Fig no.19 First order graph of Megesterol tablets with hydrotropic agents 
5.6.4. Comparision of Drug release profile of Megesterol acetate solid 
dispersion using hydrotropic agents with innovator: 
 
TIME 
(min) 
Solid dispersion with hydrotropic agents Innovator 
 
F30(A+B) 
 
 
F34(A+B+C) 
 
 
F40(U+B+C) 
 
Megrace Tablets 
2 13.75 22.40 36.71 16 
4 21.32 35.93 98.34 32.3 
6 38.02 52.06 98.96 51.8 
8 42.21 70.32  79.6 
10 65.84 98.21  99.8 
12 78.23 102.3   
 
Table 30: Comparision of Drug release profile of Megesterol acetate solid dispersion using                    
hydrotropic agents with innovator 
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Fig no.20  Comparision of Drug release profile of Megesterol acetate solid dispersion using 
hydrotropic agents with innovator 
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CHAPTER-6 
RESULTS AND DISCUSSION 
Megesterol acetate is an antineoplastic and progestational drug used in the treatment of breast 
cancer which belongs to BCS class II, which exhibits low aqueous solubility and high 
membrane permeability that leads to poor bioavailability. Hence in the present study solid 
dispersion technique and mixed hydrotropic techniques were used to enhance the solubility of 
Megesterol acetate. The following preformulation studies were conducted for the generation 
of useful information for the formulation development of most stable dosage form.   
Preformulation studies: 
The solubility of Megesterol acetate was determined in different solvents like water, alcohol, 
acetone and chloroform. It was found to be practically insoluble in water, sparingly soluble in 
alcohol, soluble in acetone, very soluble in chloroform. Form the solubility analysis studies 
megestro acetate was found to be poorly soluble drug and to enhance the solubility solid 
dispersion technique and mixed hydrotropic techniques were used in the formulation 
development. 
Micromeritic properties:   
Characterization of Megesterol acetate was conducted by different parameters and the reports 
were shown in the above table 24. The studies on angle of repose showed 25±1.5 values   
indicating good flow properties. On analyzing for density it was found that megesterol 
acetate showed bulk density value 0.68 gm/cc, tapped density value 0.78 gm/cc. Carr’s Index 
value is 9-11 % which indicates good flow properties. Hausner’s ratio of megesterol acetate 
was found to be 1.12-1.18 which indicates good flow properties. Based on the above results 
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Megesterol acetate was found to have good flow properties. Hence, direct compression 
method was used for the formulation of tablets. 
Formulation development: 
Megesterol acetate tablets were formulated as fast release tablets by using two different super 
disintegrants namely Sodium starch glycolate and Crosspovidone XL 10 from F1 to F8.  PEG 
6000 is used as carrier. The solid dispersions are prepared by solvent evaporation at weight 
ratios 1:1, 1:2, 1:3, 1:4, and 1: 5 for megesterol and PEG 6000. As the concentration of PEG 
6000 increased the % of drug release also increased upto 1:3 ratio and then upon increase in 
the conc. the drug release decreased.  
                 Megesterol acetate fast dissolving tablets were formulated by using different 
hydrotropic agents like urea, sodium benzoate, sodium acetate, sodium citrate from F9 to F43. 
From F9 to F24 four hydrotropic agents were used individually at a concs of 10%, 20%, 30% 
and 40% to increase the solubility of Megesterol acetate. From F25 to F30 a combination of 
two hydrotropic agents are used at a conc. of 20% each to get total concentration of 40%. 
From F31 to F40 a combination of three different hydrotropic agents were used at different 
concentrations to get total concentration of 40%. From these formulations F16, F30, F34 and 
F40 are optimized based on better solubility. These formulations are formulated into fast 
release tablets.  
Effect of solid dispersion:   
To enhance the solubility of Megesterol acetate solid dispersions were prepared by using PEG 
6000 as a carrier in different ratios (1:1, 1:2, 1:3, 1:4, and 1: 5) by solvent evaporation 
technique. As the conc. of PEG 6000 increased the % drug release increased up to 1:3 ratio 
then onwards the % drug release decreased in the formulation with SSG. In the formulation 
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with Crosspovidone, drug and PEG 6000 at a ratio of 1:1 showed better drug release. 
Megesterol acetate tablets with solid dispersions showed enhanced solubility compared to the 
tablet without solid dispersions.  
Effect of mixed hydrotropic technique: 
As the concentration of hydrotropic agent increased from 10% to 40% the solubility was 
enhanced, this increase in the solubility is shown in the table no.27. As the number of 
hydrotropic agents increased the solubility was enhanced and this increase in the solubility is 
shown in the table no.28. Megesterol acetate solid dispersions were prepared and this was 
formulated into tablet by including hydrotropic agents in the formulation. 
Drug release studies: 
Drug release studies were conducted for Megesterol acetate tablets by using type II 
dissolution test apparatus with paddle to rotate at 50 rpm, 900 ml of 1% SLS was taken as 
dissolution media with temperature of 37±0.5°. The rank order of drug release of Megesterol 
acetate tablets with SSG and Crosspovidone is F6 > F7 > F3 > F8 > F4 > F5 > F2 > F1.  
      The rank order of drug release for the Megesterol acetate tablets with hydrotropic agents 
is F40 > F34 > F30 > F40. The formulation with the combination of three hydrotropic agents 
showed the better drug release. 
Evaluation parameters: 
The formulated Megesterol acetate tablets were evaluated for hardness, friability, weight 
variation, thickness, wetting time, disintegration time and drug content. The results were 
reported in the table no.25.  In-vitro disintegration test was conducted for the Megesterol 
acetate tablets in 1% SLS as disintegrating medium in disintegration apparatus and the 
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disintegration time of the tablets was found to be less than 2 min and the wetting time was 
found to be 34-214 sec. 
Comparison with marketed tablets: 
The Megesterol acetate tablets formulated with solid dispersions and mixed hydrotropic 
technique showed greater drug release compared to the marketed formulation. The rank order 
of best formulation is 
Tablets with hydrotropic agents > tablets with solid dispersion > marketed tablet 
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CHAPTER - 7 
CONCLUSION 
Megesterol acetate is a novel synthetic antineoplastic and progestational drug in the treatment 
of breast cancer. It is a new chemical entity, belongs to BCS class II, which exhibits low 
aqueous solubility and high membrane permeability that leads to poor bioavailability. 
Formulation was developed by using a novel mixed hydrotropic technique. 
The summary and conclusions of investigations is as follows. 
1. The present work was carried to design and development of Megesterol acetate 
immediate release tablets for the treatment of breast cancer. 
2. The study demonstrates the preparation of fast dissolving Megesterol acetate tablets 
containing it’s by using PEG 6000 as a carrier. 
3. The carrier used in the solid dispersion and its concentration had significant affect in 
in-vitro dissolution of drug from solid dispersion. 
4. The formulated tablets showed optimized upto 1:5 ratio, but the tablet showed 
dissolution efficiency within 1 hr 70% of drug release. 
5. The study demonstrates the preparation of fast dissolving Megesterol acetate tablets 
containing its by using mixed hydrotropic technique with hydrotropic agents as urea, 
sodium benzoate, sodium acetate, sodium citrate. 
6. It can be concluded that the concept of mixed hydrotropic solid dispersion is novel, 
safe and cost-effective technique for enhancing bioavailability of poorly water-soluble 
drugs by dissolving drug in nonionized form. 
7.  The magical enhancement in solubility of Megesterol acetate is clear indication of its 
40% urea is the highest solubility among the four hydrotropic agents. 
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8. It can be concluded that these mixed hydrotropic agents are more soluble than 
individual hydrotropic agents. Finally the optimized mixed hydrotropic agent was 
dispersed equivalent weight of 20mg Megesterol acetate was taken and tablet was 
developed. 
9. The formulated Megesterol acetate tablets were evaluated for hardness, friability, 
weight variation, thickness, wetting time, disintegration time and drug content. The 
disintegration time of the tablets was found to be less than 2 min and the wetting time 
was found to be 34-214 sec. 
10.  Drug release studies were performed for the tablets of of Megesterol acetate solid 
dispersion using hydrotropic agents. Drug release studies were conducted for the 
optimized formulations F16, F30, F34 and F40. The rank order of these four 
formulations based on maximum drug release is  
                F40 (U+B+C) > F34 (A+B+C) > F30 (A+B) > F14 (B) 
11. Comparative drug release studies were performed with the marketed Megesterol 
acetate tablet (Megrace). The rank order of the formulated Megesterol acetate tablets 
and  Megrace based on maximum drug release is  
         F40 (U+B+C) > Megrace > F34 (A+B+C) > F30 (A+B) > F14 (B) 
It can be concluded that Megesterol acetate solid dispersion using hydrotropic agents         
{F40 (U+B+C)} showed better drug release than the marketed formulation. 
12. The developed Megesterol acetate tablets were able to treat breast cancer to produce 
onset of action of the drug with simple reasonable cost effective technique. 
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